Changes Include Addition of Nattokinase As First Line Therapy and Reordering of First-And Second-Line Therapies

(Changes include addition of
nattokinase as first line therapy and

reordering of first- and second-line
therapies)
Table of Contents
Summary of Suggested Therapies .......................................................................................... 3
Disclaimer ............................................................................................................................. 4
Contributors .......................................................................................................................... 4
Definition .............................................................................................................................. 4
Epidemiology......................................................................................................................... 4
Pathogenesis ......................................................................................................................... 5
Complications/ injuries caused by COVID injections. .............................................................. 7
Treatment Approach ........................................................................................................... 10
Baseline Testing................................................................................................................... 11
Anticoagulation post-vaccination and the three clinical phenotypes of the vaccine injured ... 13
Provisional approach to anticoagulation in the post-vaccine phenotypes ....................................... 15
First-Line Therapies ............................................................................................................. 17
Intermittent daily fasting or periodic daily fasts ............................................................................ 17
Ivermectin (IVM) .......................................................................................................................... 20
Moderating physical activity ......................................................................................................... 21
Low-dose naltrexone (LDN)........................................................................................................... 22
Nattokinase .................................................................................................................................22
Melatonin ....................................................................................................................................22
Magnesium ..................................................................................................................................22
Methylene blue ............................................................................................................................ 23
Sunlight and Photobiomodulation (PBM) ...................................................................................... 24
Resveratrol or a combination flavonoid ........................................................................................ 25
Probiotics/prebiotics .................................................................................................................... 26
Adjunctive/Second-Line Therapies ....................................................................................... 27
Third Line Therapies ............................................................................................................ 29
Patients with elevated homocysteine levels ......................................................................... 30
Other Potential Treatments ................................................................................................. 30
Disease-Specific Therapeutic Adjuncts ................................................................................. 34
Small fiber neuropathy (SFN)/autonomic neuropathy ...................................................................34
Generalized neurologic symptoms/“brain fog”/fatigue/visual symptoms....................................... 34
Depression ...................................................................................................................................35
Patients with elevated DIC and those with evidence of thrombosis................................................ 36
Vaccine-induced myocarditis/pericarditis...................................................................................... 36
Herpes virus reactivation syndrome .............................................................................................. 36
Tinnitus ........................................................................................................................................ 37
Ageusia and anosmia (Loss of taste and smell) .............................................................................. 37
Bell’s palsy/facial paresthesia/visual issues ................................................................................... 38
Patients with new onset allergic diathesis/features of Mast Cell Activation Syndrome (MCAS) ....... 38
Alopecia (hair loss) ....................................................................................................................... 38
References .......................................................................................................................... 40
I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 2

Summary of Suggested Therapies
First-Line Therapies Adjunctive/Second-Line Therapies Third Line Therapies
(Not symptom specific; listed (Listed in order of importance)
in order of importance)
Intermittent daily fasting or Vitamin D (4000-5000 units/day) and Hyperbaric oxygen therapy
periodic daily fasts Vitamin K2 (100 mcg/day)
Ivermectin; 0.2-0.3 mg/kg N-acetyl cysteine (NAC); 600-1500 Low Magnitude Mechanical
daily mg/day Stimulation (LMMS or
Whole-Body Vibration)
Moderating physical activity Cardio Miracle™ and L-arginine/L- “Mitochondrial energy
citrulline supplements optimizer”
Low-dose naltrexone (LDN); 1- Omega-3 fatty acids; we suggest a Hydroxychloroquine (HCQ);
4.5 mg daily combination of EPA/DHA with an 200 mg twice daily for 1-2
initial dose of 1 g/day (combined EPA weeks, then reduce as
and DHA) and increasing up to 4 tolerated to 200 mg/day
g/day (of the active omega-3 fatty
acids)
Nattokinase 100-200 mg Sildenafil with or without L-arginine- Low dose corticosteroid; 10-
(2000- 4000 Fibrinolytic Units) L-Citrulline 15 mg/day prednisone for 3
twice daily. weeks. Taper to 10 mg/day
? Low dose ASA 81 mg daily and then 5 mg/day, as
tolerated
Melatonin; 2-6 mg slow Nigella sativa; 200-500 mg
release/extended release prior encapsulated oil twice daily
to bedtime
Magnesium; 100-400 mg daily Vitamin C; 1000 mg orally two to
three times a day
Methylene blue; 10-30 mg Spermidine; 1000-2000 mg (wheat
daily germ extract) daily
Sunlight and Non-invasive brain stimulation (NIBS)
Photobiomodulation (PBM)
Resveratrol; 400-500 mg daily Intravenous Vitamin C; 25 g weekly,
together with oral Vitamin C 1000
mg (1 gram) 2-3 times per day
Probiotics/prebiotics Behavioral modification, relaxation
therapy, mindfulness therapy, and
psychological support

Disclaimer
This document is primarily intended to assist Contributors
healthcare professionals in providing appropriate This protocol was a collaborative effort
medical care for vaccine-injured patients. Patients drawing on the expertise of a dozen world-
should always consult a trusted healthcare provider renowned physicians. Dr. Pierre Kory and
before embarking on any new treatment. Dr. Paul Marik are thankful for the
contributions of: Dr. Keith Berkowitz; Dr.
Flavio Cadegiani; Dr. Suzanne Gazda; Dr.
Definition Meryl Nass; Dr. Tina Peers; Dr. Robin Rose;
Although no official definition exists for ‘post-COVID- Dr. Yusuf (JP) Saleeby; Dr. Eugene Shippen;
vaccine syndrome,’ a temporal correlation between Dr. Mobeen Syed; and Dr. Fred Wagshul.
receiving a COVID-19 vaccine and the beginning or
worsening of a patient’s clinical manifestations is We are also extremely grateful to the many
sufficient to diagnose as a COVID-19 vaccine-induced vaccine-injured people who shared their
injury when the symptoms are unexplained by other feedback and experiences with us.
concurrent causes.
Since Phase 3 and Phase 4 clinical trials are still ongoing, the full safety and toxicity profile for COVID-19
vaccines cannot be fully determined. From a bioethical perspective, cases of any new-onset or worsened
signs, symptoms, or abnormalities following any dose of COVID-19 vaccine must be considered as an
injury caused by the vaccine, until proven otherwise.
Note that there are significant overlaps between the symptoms and features of long COVID/long-hauler
syndrome and post-vaccine syndrome. However, a number of clinical features appear to be
characteristic of post-vaccine syndrome; most notably, severe neurological symptoms appear to be
more common following vaccination. To complicate matters further, patients with long COVID are often
also vaccinated, making the issue of definition more difficult.
Epidemiology
The Centers for Disease Control (CDC), National Institutes for Health (NIH), Food and Drug
Administration (FDA), and World Health Organization (WHO) do not recognize post-COVID-19 vaccine
injuries as a specific medical condition, [1] even though there is a specific ICD-10 code. Curiously, the
code U12.9 is recognized in Europe but not in the United States. There have been no prospective studies
that have accurately classified and logged the incidence of this complication; therefore, the true
magnitude of post-vaccine syndrome is unknown.
However, as of December 2nd, 2022, nearly 1.5 million adverse events had been reported. This includes
over 30,000 deaths, 185,000 hospitalizations, 15,000 heart attacks, 35,000 cases of myocarditis, and
60,000 cases of permanent disability according to OPEN VAERS, which tracks data recorded in the U.S.
Vaccine Adverse Event Reporting System (VAERS). Note that VAERS data is limited by underreporting, by
a factor of at least 30-fold. [2]
The true incidence of adverse events following COVID-19 injections, including deaths and serious vaccine
injuries, is unknown; this is complicated by the deliberate and willful manipulation of data
(underreporting) by governmental agencies in the United States, United Kingdom, Israel, and many
other countries. [2,3].

However, available data consistently and reproducibly demonstrates a rate of serious adverse events
(SAE) of about 8%. [2,3] Most importantly, the V-SAFE database administered by the CDC demonstrates
an 8% rate of SAE (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html,
https://icandecide.org/v-safe-data/. Translated to the U.S. vaccinated population, this would mean
approximately 18 million vaccine injuries. A Pollfish survey released on July 4, 2022 reported that 8.64%
of adult respondents who had received a COVID-19 vaccine in the U.S. developed a vaccine injury. A
Rasmussen report published in December 2022 reported a 7% rate of SAE those jabbed. In a nationwide
cohort of U.S. veterans, an adverse reaction was reported in 8.5% of recipients of the Pfizer vaccine and
7.9% of those receiving the Moderna vaccine. [4]
As the mainstream medical community does not recognize this serious humanitarian disaster, these
patients have been shunned and denied access to the care they need and deserve. Furthermore, there is
limited clinical, molecular, and pathological data on these patients to inform an approach to treating the
condition. Consequently, our approach to the management of vaccine-injured patients is based on the
presumed pathogenetic mechanism, pharmacologic principles, as well as the clinical observations of
physicians and patients themselves.
Pathogenesis
The spike protein, notably the S1 segment, is likely the major pathogenetic factor leading to post-
vaccine syndrome (see figure 1). [4-6] The S1 protein is profoundly toxic. Multiple intersecting and
overlapping pathophysiologic processes likely contribute to the vast spectrum of vaccine injuries: [1,7]
• The acute, immediate reaction (within minutes to hours) is likely the result of an acute type I
IgE-mediated hypersensitivity reaction. The type I response may be due to preformed antibodies
against mRNA, polyethylene glycol (PEG) [8,9], or other components of the nano-lipid particle. In
addition, PEG activates multiple ‘complement components,’ the activation of which may be
responsible for both anaphylaxis and cardiovascular collapse. [9-11] A prospective study on
64,900 medical employees, in which reactions to their first mRNA vaccination were carefully
monitored, found that 2.1% of subjects reported acute allergic reactions. [12]
• The acute myocarditis/sudden cardiac death syndrome that occurs post-vaccination (within
hours to 48 hours), noted particularly in young athletes, may be caused by a “stress
cardiomyopathy” due to excessive catecholamines produced by the adrenal medulla in response
to spike protein-induced metabolic aberrations. [13]
• The subacute and chronic myocarditis is likely the result of a spike protein-induced
inflammatory response mediated by pericytes and macrophages. [14,15]
• The subacute (days) and chronic (weeks to years) vaccine-related injuries likely result from the
overlapping effects of an S1-induced inflammatory response, the production of autoantibodies,
activation of the clotting cascade, and secondary viral reactivation.
• The inflammatory response is mediated by spike protein-induced mononuclear cell activation in
almost every organ in the body but most notably involving the brain, heart, and endocrine
organs.
• Patients with long COVID and those post-vaccination may have spike protein circulating in the
blood for as long as 15 months. [16-18] Spike protein inhibits natural killer (NK) cell activity, [19-
22] cytotoxic T-cells, and inhibits autophagy [23]; this may account for the persistence of the
spike protein.

• The lipid nanoparticles (LNP) themselves are highly pro-inflammatory, as evidenced by excessive
neutrophil infiltration, activation of diverse inflammatory pathways, and production of various
inflammatory cytokines and chemokines. [24-26]
• Neuro-COVID, the neurological manifestations related to the spike protein, are related to the
complex interplay of neuroinflammation, [27] production of amyloid and prion protein, [28-34]
autoantibodies, microvascular thrombosis, and mitochondrial dysfunction. [35]
The spike protein of SARS-CoV-2 Figure 1. Complex pathophysiology of spike-related

has extensive sequence
homology with multiple
vaccine-induced disease
endogenous human proteins and
could prime the immune system
toward development of both
auto-inflammatory and
autoimmune disease. [11] As a
consequence of molecular
mimicry with the spike protein, a
diverse spectrum of
autoantibodies has been
reported. [36-46] These
autoantibodies are the likely
cause of Guillain-Barré Syndrome
(GBS), transverse myelitis,
immune thrombocytopenia, and
Small Fiber Neuropathy
(SFN)/Autonomic neuropathy.
[47-54]
Many of these antibodies are

directed against G-protein-
coupled cell membrane
receptors. [43,45] Anti-neuronal antibodies likely contribute to the myriad of neurological findings.
SFN/autonomic neuropathy appears to be a characteristic disorder following vaccination and is strongly
associated with a vast array of autoantibodies. Further, autoantibodies may result in a number of
specific syndromes, including anti-phospholipid syndrome, systemic lupus erythematosus (SLE),
rheumatoid arthritis, etc.
The spike protein is highly thrombogenic, directly activating the clotting cascade; in addition, the clotting
pathway is initiated via inflammatory mediators produced by mononuclear cells and platelets. [6]
Activation of the clotting cascade leads to both large clots (causing strokes and pulmonary emboli) as
well as micro clots (causing microinfarcts in many organs, but most notably the brain). Emerging data
suggest that the vaccines can induce an allergic diathesis (eczema, skin rashes, asthma, skin and eye
itching, food allergies, etc.) This appears to be due to a unique immune dysregulation with antibody
class switching (by B cells) and the production of IgE antibodies. There is an overlap with Mast Cell
Activation Syndrome (MCAS) and the distinction between the two disorders is not clear. [55,56]
However, by definition MCAS has no identifiable causes, is not caused by allergen-specific IgE, and has
no detectable clonal expansion of mast cells. [55]

And finally, due to altered immune function, the activation of dormant viruses and bacterial pathogens
may occur, resulting in reactivated Herpes Simplex, Herpes Zoster, Epstein Barr Virus (EBV), and
cytomegalovirus (CMV) infection, as well as reactivation of Lyme disease and mycoplasma. [57-60]
The common factor underlying the pathogenic mechanism in the vaccine-injured patient is “immune
dysregulation.” The development of immune dysfunction and the severity of dysfunction likely result
from several intersecting factors, including:
• Genetics: First-degree relatives of patients who have suffered a vaccine injury appear to be at a
very high risk of vaccine injury. Those patients with a methylenetetrahydrofolate reductase
(MTHFR) gene mutation [61] and those with Ehlers-Danlos type syndromes may be at an
increased risk of injury. MTHFR C677T polymorphism is the most common MTHFR single
nucleotide polymorphism (SNP) and the most common genetic cause of hyper-
homocysteinemia. [62] Increased homocysteine levels have been linked to worse outcomes in
patients with COVID-19. [63,64] Increased homocysteine levels may potentiate the
microvascular injury and thrombotic complications associated with the “spikopathy”. [62,65]
• mRNA load and quantity of spike protein produced: This may be linked to specific vaccine lots
that contain a higher concentration of mRNA. [1] The Moderna vaccine is reported to contain
100 ug of mRNA as compared to 30 ug mRNA for the Pfizer vaccine (10 ug in children 5-11 years
of age), however, it is likely that the true concentration varies widely.
• Sex: It appears that about 80% of vaccine-injured patients are female. Furthermore, treatment
with estrogens has been reported to worsen or precipitate an event/relapse. Women are known
to be at a much higher risk of autoimmune diseases (especially SLE) and this likely explains this
finding. Estrogens interfere with glucocorticoid receptor signaling. [66] In addition, estrogens
modulate B and T cell function.
• Underlying nutritional status and comorbidities: Certain preexisting conditions may likely have
primed the immune system to be more reactive after vaccination. This includes those with
preexisting autoimmune disorders and chronic inflammatory diseases such as Lyme disease.
Those patients with a poor nutritional status including those with deficiencies of nutrients such
as Vitamin D, Vitamin B12, folate, and magnesium may be at an increased risk of injury.
Complications/ injuries caused by COVID injections

Over 3,000 peer-reviewed articles have been published on COVID vaccine injuries. Find links to these
studies at COVID Vaccine Injuries, REACT19, and on Substack. A selection of symptoms is listed below:
• Myocarditis, pericarditis, stress • Thrombocytopenia

cardiomyopathy (contraction band • Thrombotic thrombocytopenic purpura
necrosis) • Idiopathic thrombocytopenic purpura
• Takotsubo cardiomyopathy • Henoch Schönlein Purpura
• Acute coronary syndrome • Immune-mediated hemolysis
• Hypertension • Reactivation and exacerbation of
• MIS-V, Multisystem Inflammatory chronic underlying diseases/disorders
Syndrome • Immune dysregulation
• Thrombosis, including pulmonary • Metabolic dysregulation (diabetes)
emboli and stroke (prothrombotic • Menstrual irregularities
state) • Menorrhagia
• Cerebral venous thrombosis

• Amenorrhea • Sensorineural hearing loss
• Spontaneous abortion • Vestibulitis
• Vulval and vaginal ulcers • Severe headaches and migraines
• Vasculitis, including Leukocytoclastic • Seizures and status epilepticus
vasculitis, Granulomatous vasculitis, • Prion disease i.e., Mad Cow Disease
microscopic polyangiitis. • Acute macular retinopathy
• Guillain-Barre Syndrome • Uveitis
• Acute Myelitis • Acute Optic Neuropathy
• Systemic lupus erythematosus • Rhabdomyolysis
• Bell’s Palsy • Keratolysis
• Stills disease. • Herpes Keratitis
• Sweets syndrome • Inflammatory myositis
• Facial nerve palsy • Immune mediate hepatitis
• Multiple sclerosis • Pancreatitis
• Polyarthralgia/polyarthritis • Acute kidney injury
• Cryoglobulinemia • Nephrotic syndrome
• Lymphadenopathy, local and • ANCA glomerulonephritis
generalized. • Skin reactions including rashes,
• Anaphylaxis urticaria, Pityriasis rosea
• Allergic reactions • Pemphigus vulgaris
• Intracerebral hemorrhage • Hemorrhagic bullous pyoderma
• Strokes (thrombotic strokes) gangrenosum
• Generalized neurological symptoms • Eosinophilic dermatosis
including “brain fog”, cognitive decline, • Alopecia, including alopecia areata
memory loss. • Psoriasis
• Alzheimer’s Disease like syndrome • Toxic epidermal necrolysis
• Acute hyperactive encephalopathy • Erythema multiforme
• Acute disseminated encephalomyelitis • Hemophagocytic histiocytosis
• Neuromyelitis Optica • Varicella Zoster infection
• Ageusia and anosmia • Epstein-Barr viral reactivation
• Aphasia • CMV reactivation
• Depression • Herpes Simplex reactivation
• New onset panic disorders • Zoster meningitis
• New onset psychosis and delirium • Ramsay Hunt syndrome
• Small fiber neuropathy • Thyroiditis
• Autonomic neuropathy • Tolosa-Hunt syndrome
• POTS syndrome (postural Orthostatic • Acute eosinophilic pneumonia
Tachycardia syndrome) • Cancer recurrences
• Mononeuritis multiplex, • New and unusual malignancies,
polyneuropathy including Angioimmunoblastic T Cell
• Acute inflammatory neuropathies Lymphoma
• Tinnitus (severe and persistent)

The most common symptoms recorded in post-vaccine syndrome are presented in Figure 2. On average,
patients reported 23 distinct symptoms. (Results from PVS Germany Survey; Reproduced with
permission from React19/PVS Germany https://react19.org/post-vaccine-syndrome-survey-results/
Figure 2. Vaccine injury is a multi-symptomatic disease*

Treatment Approach
A number of principles are essential for the optimal A note about anesthesia and
management of post-vaccine syndrome: surgery:
It is important to emphasize that there are no published reports Patients should notify their
detailing the management of vaccine-injured patients. Our anesthesia team if using the
treatment approach is, therefore, based on the postulated following medications and/or
pathogenetic mechanism, pharmacologic principles, clinical nutraceuticals, as they can
observation, and feedback from vaccine-injured patients. increase the risk of Serotonin
syndrome (SS) with opioid
The core problem in post-vaccine syndrome is chronic “immune administration:
dysregulation.” The primary treatment goal is to help the body
• Methylene blue
to restore and normalize the immune system—in other words,
• Curcumin
to let the body heal itself. We recommend the use of immune-
• Nigella Sativa
modulating agents and interventions to dampen and normalize
• Selective Serotonin
the immune system rather than the use of immunosuppressant
Reuptake Inhibitors
drugs, which may make the condition worse. However, the
(SSRIs)
concomitant use of a controlled course of an
immunosuppressant drug may be appropriate in patients with
specific autoimmune conditions.
The treatment strategy involves two major approaches i) promote autophagy to help rid the cell of the
spike protein and ii) interventions that limit the toxicity/pathogenicity of the spike protein.
Treatment must be individualized according to each patient’s presenting symptoms and disease
syndromes. Not all patients respond equally to the same intervention; this suggests that the treatment
must be individualized according to each patient’s specific response. A peculiar finding is that a
particular intervention (e.g., Hyperbaric oxygen therapy) may be lifesaving for one patient and totally
ineffective for another.
Patients should serve as their own controls and the response to treatment should dictate the
modification of the treatment plan. One (or at most two) new interventions should be added at a time in
order to evaluate what helps the patient and those interventions that are not helpful.
Early treatment is essential; the response to treatment will likely be attenuated when treatment is
delayed.
Patients should be started on the primary treatment protocol; this should, however, be individualized
according to the patient’s particular clinical features. The response to the primary treatment protocol
should dictate the addition or subtraction of additional therapeutic interventions. Second-line therapies
should be started in those who have responded poorly to the core therapies and in patients with severe
incapacitating disease.
Patients with post-vaccine syndrome must not receive further COVID-19 vaccines of any type. Likewise,
patients with long COVID should avoid all COVID vaccinations.

Patients with post-vaccine syndrome should
do whatever they can to prevent themselves
from getting COVID-19. This may include a
preventative protocol (see FLCCC protocols).
In the event they do contract the virus or

suspect infection, early treatment is
essential (see FLCCC protocols). COVID-19
will likely exacerbate the symptoms of
vaccine injury.
Vaccine-injured patients are frequently

desperate to try any medication or
intervention they believe may help them.
Unfortunately, unscrupulous providers will
take advantage of these very vulnerable
patients and sell them expensive and
unproven remedies.
Patients should avoid unscientific and poorly validated “Spike Protein Detox” programs.
Hyperbaric oxygen therapy (HBOT) should be considered in cases of severe neurological injury and in
patients showing a rapid downhill course (see below).
Once a patient has shown a clinical improvement the various interventions should be reduced or
stopped one at a time. A less intensive maintenance approach is then suggested.
Baseline Testing
Post-vaccine patients are often subjected to an extensive battery of diagnostic tests. These tests are
rarely helpful, usually confusing the situation and leading to inappropriate therapeutic interventions.
Patients frequently undergo diagnostic tests that are “experimental,” unvalidated, and clinically
meaningless; patients should avoid getting such tests. Remember the dictum: Only do a test if the
result will change your treatment plan. We recommend a number of simple, basic screening tests that
should be repeated, as clinically indicated, every 4 to 6 months.
• CBC with differential and platelet count

• Standard blood chemistries, including liver function tests
• D-Dimer—as a marker of clotting activation. Those with a markedly elevated D-dimer should
probably undergo screening for an inherited thrombophilia.
• CRP—as a marker of ongoing inflammation (A comprehensive extensive cytokine/chemokine
panel is unnecessary and very costly, and the results will not change the treatment approach.)
• Early morning cortisol—some patients develop autoimmune adrenal failure)
• TSH—to exclude thyroid disease
• Homocysteine level (normal 5-15 μmol/l)
• HbA1C—Vaccine-injured patients are at an increased risk of developing diabetes
• Troponin and pro-BNP to exclude cardiac disease.

• CMV, EBV (early antigen-D IgG or nuclear antigen IgG), Herpes simplex, HHV6 and mycoplasma
serology/PCR—to exclude viral/bacterial reactivation (In patients who respond poorly to
therapy, it may be helpful to check for Lyme (Bb), Bartonella and Babesia tick-borne diseases—
e.g., https://igenex.com/ and https://www.mdlab.com/). [60]
• Vitamin D level (25OH Vitamin D)
• In patients with allergic features and those who experienced an acute reaction to the vaccine,
the following tests may be helpful: eosinophil count; IgE levels, RAST testing, and/or skin testing.
Serum tryptase, serum histamine, and/or 24-h urine N-methylhistamine should be considered
in MCAS. [55]
• In patients who present with deep venous thrombosis (DVT) and/or pulmonary embolism soon
after vaccination screening for an inherited thrombophilia is suggested. [67]
• Limited screening autoantibodies. Lupus anticoagulant (if positive B2 microglobulin etc.) and
ANA. Vaccine-injured patients, particularly those with autonomic dysfunction/SFN frequently
have an extensive array of autoantibodies directed against G-protein coupled cell surface
receptors, [43,45] ACE-2, [68] neurons, myelin, and other self-epitopes. The presence or
absence of these antibodies has little impact on the management of these patients.
Figure 3. Time course of sudden cardiac deaths following COVID-19 vaccination

Anticoagulation post-vaccination and the three
clinical phenotypes of the vaccine injured
The need for anticoagulation in post-vaccination patients is a very complex and controversial issue.
Three distinct clinical phenotypes with differing pathophysiological and clinical presentations exist (see
Figure 3).
• The first is the “typical” post-vaccine, muti-symptomatic syndrome characterized typically by

fatigue, brain fog, and other multiple complex symptoms (see figure 2). This syndrome is
characterized by microvascular inflammation and microvascular thrombosis as part of the
complex pathophysiology of post-vaccine spike related disease (see Figure 1).
• The second is that of sudden cardiac death within the first 2 weeks (usually first 7 days)
following the last dose of vaccination. The early sudden deaths are likely arrhythmogenic deaths
related to catecholamine-induced contraction band necrosis and spike-induced inflammatory
myocarditis (often focal myocarditis).
• The third phenotype includes those otherwise healthy patients who “die suddenly” 4 to 6
months after the last dose of the COVID vaccine. Patients with this phenotype typically lack the
typical symptoms characteristic of post-vaccine syndrome. While the pathology of this
syndrome has not been studied (as it has been dismissed by governmental agencies), it is likely
the result of a progressive spike-induced endothelialitis complicated by thrombosis.
Dr. Steven R. Gundry, a cardiac surgeon, performed a biomarker-based cardiac risk assessment score
(the PULS Cardiac Test now available as the SMARTVascular Dx provided by SmartHealth Dx
https://www.smarthealthdx.com) in 566 patients 2 to 10 weeks following the 2nd mRNA COVID shot
and compared this score to the PULS score drawn 3 to 5 months prior to the jab. [69] The PULS score is a
marker of endothelial inflammation. In this study, the 5-year Acute Coronary Risk Score (ACS) increased
from a baseline of 11% to 25% after the jab. This study clearly demonstrates that the mRNA ‘jabs” lead
to progressive endothelial inflammation.
To complicate matters further, the clots (micro-clots and macro-clots) that develop in patients with
spike-related disease are distinctly different from “usual clots” and have a number of unique
characteristics. These clots are rich in fibrin with amyloid-like fibrils and are more resistant to
fibrinolysis. Immunohistochemical staining demonstrates a high concentration of spike protein within
the clots; this is important as spike protein via multiple mechanisms activates clotting as well as altering
the structure of fibrin resulting in amyloid-like fibrils.
Based on this information, it would seem intuitive that the use of anti-coagulants and the approach to
treatment would be different for these three phenotypes; however, the ideal approach has yet to be
determined. A provisional approach to anticoagulation is provided below. A review of the
pharmacological properties of the various anticoagulants available to the healthcare provider is
provided. The general approach to the management of the multi-symptom vaccine syndrome is then
reviewed.
The greatest risk with the use of anticoagulant drugs is clinically significant bleeding. A number of
factors increase the risk of bleeding; [70-72] these include age > 65 years (advanced age is a major risk

factor for bleeding), hypertension, renal impairment, diabetes, previous stroke, a previous bleed, and
male sex. Furthermore, the risk of bleeding increases exponentially as the number of anticoagulant/anti-
platelet drugs is increased. [71,73]
Antiplatelet drugs:
Aspirin (ASA): ASA produces a clinically relevant antiplatelet effect by irreversibly acetylating the active
site of cyclooxygenase-1 (COX-1), which is required for the production of thromboxane A2, a powerful
promoter of platelet aggregation. These effects are achieved by daily doses of 75 mg (and higher). The
major adverse effect is bleeding. Bleeding most commonly occurs in the gastrointestinal tract and is
rarely fatal. Bleeding also occurs at other sites, with intracranial bleeding being the rarest
(approximately 4 per 10,000) but the most serious (with a 50% case fatality rate).
Clopidogrel (Plavix): Clopidogrel requires in vivo biotransformation to an active thiol metabolite. The
active metabolite irreversibly blocks the ADP receptors on the platelet surface, which prevents
activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Similar to ASA,
platelets blocked by clopidogrel are affected for the remainder of their lifespan (~7 to 10 days). The
usual dose is 75mg daily.
Direct oral anticoagulants (DOAC):
Apixaban (Eliquis): Inhibits platelet activation and fibrin clot formation via direct, selective, and
reversible inhibition of free and clot-bound factor Xa (FXa). FXa, as part of the prothrombinase complex
consisting also of factor Va, calcium ions, and phospholipid, catalyzes the conversion of prothrombin to
thrombin. Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin. Typical
dose is 2.5 to 5mg twice daily.
Rivaroxaban (Xarelto): Mechanism of action similar to apixaban. Typical dosage is 10–20 mg once daily
with the evening meal.
Oral Fibrinolytic agents:
Nattokinase: Nattokinase (NK) is a serine protease purified and extracted from natto, a traditional
Japanese (cheese like) food produced from the fermentation of soybeans with the bacterium, Bacillus
subtilis. [74-76] Recent studies demonstrated that a high natto intake was associated with decreased
risk of total cardiovascular disease mortality and, in particular, a decreased risk of mortality from
ischemic heart diseases. [77]
Nattokinase has potent fibrinolytic, antithrombotic, and antiplatelet activity. [74,75,78-81] NK degrades
fibrin directly and also increases the release of tPA with a subsequent increase in the formation of
plasmin. [82] Furthermore, NK enhances fibrinolysis through cleavage and inactivation of PAI-1. [76,81]
In a study comparing the antiplatelet effects of NK and aspirin, NK was shown to display excellent
antiplatelet aggregation and antithrombotic activities in vitro and in vivo, inhibiting thromboxane B2
formation from collagen-activated platelets. [83] In addition, in both animal and human studies, NK also
has antihypertensive, anti-atherosclerotic, lipid-lowering, and neuroprotective actions. [75,81,84] Of
particular relevance to patients with spike-related clotting, nattokinase causes the proteolytic cleavage
of both spike protein and amyloid proteins. [85] In a randomized study, NK proved to be more effect
than statins (simvastatin) in reducing carotid artery atherosclerosis. [86]

Chen et al demonstrated that high dose NK (10 800 Fibrinolytic Units [FU]/day; ~ 500 mg/day) reduced
the thickness of the carotid artery intima-media and the size of the carotid plaque. [87] The authors
reported a synergistic effect between NK and ASA.
Studies indicate that an oral administration of NK can be absorbed by the intestinal tract. [84,88] NK,
unlike most proteins, is more resistant to the highly acidic gastric fluids in the stomach and can be
absorbed in the later sections of the digestive tract.
The optimal dose of nattokinase is unclear, however, a dose of 100-200 mg (2000- 4000 FU/day) twice
daily has been suggested.
While NK appears to have an excellent safety profile, [87,89] bleeding has rarely been reported in
patients with risk factors for bleeding (advanced age, renal failure, hypertension, concomitant ASA, etc).
[90,91] High concentrations of vitamin K2 in natto can reduce the INR when coadministered with
warfarin; this may also occur with nattokinase supplements if vitamin K2 is not removed during the
production process. Information regarding safety and efficacy in pregnancy and lactation is lacking.
Lumbrokinase: Lumbrokinase derives from a group of enzymes extracted from earthworms. The
enzymes are sourced mostly from the earthworm Lumbricus rubellus. Lumbrokinase has very similar
pharmacodynamic properties to Nattokinase, i.e., it directly breaks down fibrin clots, inhibits PAI-1
activity, enhances t-PA activity, has antiplatelet activity, and proteolytically cleaves amyloid. [92-94] The
recommended dose is 300,000 to 600,000 IU/day (20-40 mg). Lumbrokinase has been widely used for
patients with acute ischemic stroke in China; however, because rigorously designed studies are lacking,
the safety and efficacy of lumbrokinase remains largely unknown. [95] As the pharmacology, clinical
effectiveness, and safety of nattokinase has been assessed in a number of experimental and clinical
studies, this agent is preferred over lumbrokinase.
Provisional approach to anticoagulation in the post-vaccine phenotypes

For more information see I-PREVENT: Vaccine Injury
• “Typical” post-vaccine syndrome. Nattokinase 100-200mg (2000 – 4000FU) twice daily is

recommended. Low-dose aspirin (ASA) (81mg daily) can be added in patients at a low risk of
bleeding complications (see risk factors). Pretorius et al reported on the use of “triple therapy”
in 24 patients with long COVID and the presence of fibrin amyloid microclots on live blood
analysis. [96] Patients were treated with one month of dual antiplatelet therapy (Clopidogrel
75mg/Aspirin 75mg) once a day, as well as Apixaban 5 mg twice a day. This was followed by ASA
and nattokinase alone. These authors reported that “each of the 24 treated cases reported that
their main symptoms were resolved, and this was also reflected in a decrease of both the fibrin
amyloid microclots and platelet pathology scores.” Triple therapy can be considered in patients
at low risk of bleeding (see risk factors) who have responded poorly to the combination of ASA
and nattokinase alone; however, triple therapy should only be instituted under the direct
supervision and monitoring of a clinician with expertise in the management of anti-coagulation.
• Early sudden death. Early post-vaccination sudden cardiac death is a condition of young
patients, especially men. This is the most problematic phenotype with no clear guidance on the
prevention of this fatal condition (except to stop vaccination in this high-risk group). Many of
the deaths occur during physical activity (sudden death in soccer players); consequently,

vigorous physical activity should be avoided for at least 3 weeks following vaccination.
Magnesium supplementation (see section on magnesium) may reduce the risk of arrhythmic
deaths. The role of anti-inflammatory agents (e.g., curcumin, resveratrol, Nigella sativa, Omega-
3 fatty acids) is unclear.
• Late cardiac deaths (4-6 months after “jab”). Ideally, these asymptomatic patients should be risk
stratified with the initiation of prophylactic measures in the moderate to high-risk groups.
Unfortunately, as this catastrophic disorder is not generally recognized and has therefore not
been studied, there is no data to allow for risk stratification. Serial cardiac risk biomarker
analysis may be helpful; [69] however, this test is expensive and not widely available. In the
absence of a risk-stratified approach, the following interventions may reduce the risk of acute
myocardial infarction and sudden death: [97]
o Nattokinase 100-200 mg twice daily

o ASA 81 mg daily (in those with low risk of bleeding)
o Omega-3 fatty acids 2-4 g daily
o Resveratrol or flavonoid combination supplement
o Co-enzyme Q (CoQ) 200-400 mg/day.
o Melatonin 3-10 mg at night (slow release/extended release).
o Bromelain 500 mg twice daily +/- N-acetyl cysteine (NAC) 600 mg twice daily.
o Berberine 500-600 mg twice daily.
o “Green based diet”- Low carbohydrate, high fat diet (low in omega-6 vegetable oils)

First-Line Therapies
(Not symptom specific; listed in order of importance)
Intermittent daily fasting or periodic daily fasts

Fasting has a profound effect on promoting immune system “A little starvation can really do
homeostasis, improving mitochondrial health, and increasing stem more for the average sick man
cell production. [98-104] than can the best medicines
and the best doctors.”
Fasting stimulates the clearing of damaged mitochondria —Mark Twain
(mitophagy), misfolded and foreign proteins, and damaged cells (1835-1910)
(autophagy).
Dosing and administration

A number of intermittent fasting plans can be adapted and modified to best suit the patient’s lifestyle.
[98] For timed fasting, begin slowly: start with a 12-hour eating window 5 days a week and reduce
weekly to an 8-hour eating window 7 days a week. This eating window can be shortened to 4 hours or
less over time. Timed fasting can be interspersed with 36- to 48-hour fasts. For caloric fasting, eat
normally for 5 days and fast for 2 days by restricting caloric intake on those days to 500-1000 calories
per day. Intermittent fasting/timed restricted eating needs to be coupled with a diet that consists of
“real food,” minimizing the intake of processed foods, sugar, fructose, and omega-6 polyunsaturated
fatty acids. [105]
It is important to stay well-hydrated during fasting periods; drink lots of water and/or an electrolyte
solution. In his book the “Complete Guide to Fasting,” Jason Fung, MD recommends drinking coffee with
added coconut oil (medium chain triglycerides)/heavy cream (no CHO or protein) during fasting. [98]
Remarkably, caffeine stimulates autophagy, [106-108] while coconut oil has numerous health benefits.
[109-111]
Mechanisms
Autophagy plays an important role in preventing Alzheimer’s disease by removing amyloid protein.
Autophagy likely removes spike protein and misfolded proteins induced by the spike protein. Autophagy
may therefore play a critical role in reversing the “spikopathy” induced by COVID injections. Indeed,
activation of autophagy may be the only mechanism to remove intracellular spike protein.
Cautions and contraindications

Note that fasting is contraindicated in patients younger than 18 (impairs growth), malnourished patients
(BMI < 20 kg/m2), and during pregnancy and breastfeeding. Patients with diabetes, gout, and serious
underlying medical conditions should consult their primary care physician before undertaking fasting, as
changes in their medications may be required and these patients require close monitoring.
Proton pump inhibitors (PPI) should be avoided as they prevent the acidification of lysosomes and block
autophagy. [112] Patients may develop rebound esophagitis if a PPI is suddenly discontinued. H2-
blockers (famotidine, ranitidine, etc.) may be an alternative. Aloe Vera Stomach Formula (Aloe Vera
contains over 200 biologically active components) and diluted Apple Cider vinegar (tastes awful) have
been suggested as an alternative to a PPI; however, there is limited data to support these interventions.
[113,114]

Chloroquine and hydroxychloroquine (HCQ) act by alkalinizing lysosomes and therefore interfere with
the autophagy process. [115,116] Based on this data, HCQ may limit the benefit of intermittent fasting.
Paradoxically, while autophagy may prevent cancers, autophagy may promote the growth of cells that
have already undergone malignant transformation. Cancer cells, which have an increased metabolic
demand for energy and macromolecular building blocks to proliferate, show elevated levels of
autophagy to recycle nutrients. [117] High-dose HCQ (more than 800 mg/day) has been demonstrated
to improve the outcome of patients with certain cancers by inhibiting autophagy. [118-122] This data
suggests caution in activating autophagy (fasting) in patients with cancer. However, “fasting mimicking
diets” as an adjunct to chemotherapy have been reported to improve quality-of-life indicators. [123-
125] Patients should discuss fasting and fasting protocols with their treating oncologist.
Women and fasting

Several studies have suggested that intermittent fasting may not be as beneficial for pre-menopausal
women as it is for men. This is likely because calorie restriction in females is associated with changes in
the release of hypothalamic hormones, which may impact the menstrual cycle.
Although there are no comparable human studies, experiments in rats have shown that 3–6 months of
alternate-day fasting caused a reduction in ovary size and irregular reproductive cycles in female rats.
[126] Similarly, in a murine model, Kumar and Kaur demonstrated that intermittent fasting negatively
influences reproduction in young animals due to its adverse effects on the complete hypothalamus-
hypophysial-gonadal axis. [127] However, it should be noted that, in this study, the female rats were
very young (3 months old), which corresponds to a human aged 9 years old. [128] Heilbronn et al
reported that alternate-day fasting adversely affected glucose tolerance in nonobese women but not in
nonobese men. [129]
Changes in gonadotropins during fasting have only been assessed in one clinical trial to date. In this trial
by Li et al., young women with obesity and polycystic ovarian syndrome (PCOS) followed an early 8-hour
time-restricted eating regimen for 5 weeks. [130] At the conclusion of the study, LH and FSH remained
unchanged. It is possible that alternate-day fasting results in greater disruption of the hypothalamus-
hypophysial-gonadal axis than does 8-hour time-restricted eating. In addition, the timing of time-
restricted eating may be important. Jakubowicz et al demonstrated that a large meal later in the day (at
dinner) augmented estrogen levels in women with PCOS as compared to eating earlier in the day. [131]
There are many anecdotal stories of women who have experienced changes to their menstrual cycles
after starting intermittent fasting (likely alternate-day or fasting > 24 hours). For this reason, pre-
menopausal women may need to follow a modified approach. To reduce any adverse effects, women
should take a mild approach to fasting: shorter fasts and fewer fasting days. We would suggest
beginning a program of time-restricted eating consisting of fasting for 12 hours for two to three days a
week and increasing from there (see Figure 4). Furthermore, the fasting window should begin at least 4
hours before going to sleep.
Fasting days should be nonconsecutive and spaced evenly across the week (for example, Monday,
Wednesday, and Friday). With time, the fasting window can slowly be increased to 16 hours and the
number of fasting days per week increased. It has been suggested (with no published data) that the
cycle of intermittent fasting be linked to the menstrual cycle; namely, with a 16-hour fasting window
from day 1 to day 10 (including Keto), a 12-hour fasting window on days 11-16 (with Keto), and a
“normal” dietary pattern on days 17-28 (including more carbohydrates with a less strict Keto diet). In

women who follow a more conservative intermittent fasting regimen, the addition of resveratrol and
spermidine may augment autophagy (see below).
Figure 4. An Intermittent Fasting Plan for Pre-Menopausal Women
Feedback on “productive approach” from a pre-menopausal patient:
“I started 14:10 daily for a couple of weeks (14 hours fasting, eating for 10 hours); Then 16:8
daily for another two weeks (16 hours fasting; eating for 8 hours); Finally,18:6 for 3-4 days
out of a week with the rest of the week 16:8.
I try to stop any oral intake other than water three hours before bedtime — I found this is the
most critical factor in how I feel the next day. I have not noticed any side effects from
intermittent fasting other than a few pounds of unintentional weight loss. However, I have
experienced an improvement in my health.”
____________________________

Ivermectin (IVM)
It is likely that ivermectin and intermittent fasting act synergistically to rid the body of the spike protein.
Ivermectin binds to the spike protein, aiding in the elimination by the host. [132-134] A trial of
ivermectin should be included in the first-line treatment approach. Ivermectin has potent anti-
inflammatory properties. [135-137]

Ivermectin is best taken with or just following a meal for greater absorption.
It appears that vaccine-injured patients can be grouped into two categories: i) ivermectin responders
and ii) ivermectin non-responders. This distinction is important, as the latter group is more difficult to
treat and requires more aggressive therapy.
Based on the most updated clinical experiences in our collaborative network, we propose the following
treatment approach:
o Initiate therapy with 0.3 mg/kg daily. Reassess for improvements in 2-3 weeks.
▪ If no improvement is noted, a trial of discontinuation should be initiated. Be aware that

in a minority of cases, patients who did not initially sense a benefit with use will report
worsening of symptoms when IVM is discontinued. These patients should be restarted
on daily ivermectin.
▪ If improvements or a reduction in symptoms are noted, a 10-day trial of a higher dose

should be initiated, typically by doubling the dose (0.6mg/kg day), given that a
significant proportion of ivermectin-responsive patients report even greater benefits at
higher doses.
▪ If the patient reports additional benefit with doubling the initial dose, continue patient
on 0.6mg/kg daily.
▪ If the patient does not report additional benefit at the higher dose, reduce ivermectin to
the initial dose of 0.3mg/kg daily.
o For ivermectin responders, prolonged and chronic daily treatment is often necessary to support
their recovery. In many, if the daily ivermectin is discontinued worsening symptoms often recur
within days.
o Weaning/discontinuation – once patients have clinically improved to a desirable extent on a

treatment regimen that includes daily ivermectin, we maintain the treatment regimen for at
least 2 months before trying to decrease dose and/or reduce the frequency of ivermectin.
Weaning and/or discontinuing is not possible in many patients due to recurrence of symptoms.

Due to the possible drug interaction between quercetin and ivermectin, these drugs should not be taken
simultaneously (i.e., should be staggered morning and night). The safety of ivermectin in pregnancy is
uncertain and this drug should therefore be avoided in the first trimester of pregnancy. [138]

Table 1. How to Calculate Ivermectin Dose
Use the table below to help determine how much ivermectin you should take, based on your body weight and
the specific recommendation in the protocol or guide you are following. Based on the dosage, you can then
determine how many pills or capsules you need to take, bearing in mind that ivermectin is available in different
strengths (e.g., 3, 6, or 12 mg) and administration forms (tablets, capsules, drops, etc.). Remember that tablets
can be halved for more accurate dosing, while capsules cannot.
For example: A 160 lb. person needs to take a daily dose of 0.3 mg/kg. Her doctor has provided her with 3 mg
tablets. Based on this table, her daily dose should be 21-23 mg, so she should take 7 tablets.
How much do I weigh? The protocol says…

In pounds In kilos “0.2 mg/kg” “0.3 mg/kg” “0.4 mg/kg” “0.6 mg/kg”
So my dose is…
70–90 32–41 6-8 mg 10-12 mg 13-16 mg 19-25 mg
91–110 41–50 8-10 mg 12-15 mg 17-20 mg 25-30 mg
111–130 50–59 10-12 mg 15-18 mg 20-24 mg 30-35 mg
131–150 60–68 12-14 mg 18-20 mg 24-27 mg 36-41 mg
151–170 69–77 14-15 mg 21-23 mg 27-31 mg 41-46 mg
171–190 78–86 16-17 mg 23-26 mg 31-35 mg 47-52 mg
191–210 87–95 17-19 mg 26-29 mg 35-38 mg 52-57 mg
211–230 96–105 19-21 mg 29-31 mg 38-42 mg 58-63 mg
231–250 105–114 21-23 mg 32-34 mg 42-45 mg 63-68 mg
251–270 114–123 23-25 mg 34-37 mg 46-49 mg 68-74 mg
271–290 123–132 25-26 mg 37-40 mg 49-53 mg 74-79 mg
291–310 132–141 26-28 mg 40-42 mg 53-56 mg 79-85 mg
Moderating physical activity

Patients with long COVID and post-vaccine symptoms frequently suffer from severe post-exertional
fatigue and/or worsening of symptoms with exercise. [139,140] Aerobic exercise is reported to be one of
the worst therapeutic interventions for these patients.

We recommend moderating activity to tolerable levels that do not worsen symptoms, keeping the
patient’s heart rate under 110 BPM. Furthermore, patients need to identify the activity level beyond
which their symptoms worsen, and then aim to stay below that level of activity. Stretching and low-level
resistance exercises are preferred over aerobic exercises.
Mechanisms
Similar to patients with chronic fatigue syndrome, post-exertional fatigue may be related to
mitochondrial dysfunction and the inability to augment production of ATP. [139,141,142] Magnetic
resonance–augmented cardiopulmonary exercise testing suggests failure to augment stroke volume as a
potential mechanism of exercise intolerance in patients with long COVID. [143]

Low-dose naltrexone (LDN)
LDN has been demonstrated to have anti-inflammatory, analgesic, and neuromodulating properties.
[144,145]

1-4.5 mg daily. Begin with 1 mg/day and increase to 4.5 mg/day, as required. May take 2 to 3 months to
see the full effect.
Nattokinase
100-200 mg (2000-4000 FU) twice daily. Aspirin/ASA 81 mg daily can be added in low-risk patients.
Mechanisms
Nattokinase is a highly effective fibrinolytic and antiplatelet agent which targets the abnormal clotting in
the spike injured patient. In addition, nattokinase has been demonstrated to lyse extracellular spike
protein; this may further enhance the anti-clotting action of nattokinase.
Melatonin
Melatonin has anti-inflammatory and antioxidant properties and is a powerful regulator of
mitochondrial function. [146-150]

2-6 mg slow release/extended release prior to bedtime. The dose should be started at 750 mcg (μg) to 1
mg at night and increased as tolerated.

Patients who are slow metabolizers may have very unpleasant and vivid dreams with higher doses.
Magnesium
A starting dose of 100 to 200 mg daily is suggested, increasing the dose as tolerated up to 300 mg
(females) to 400 mg daily. Endpoints of treatment include an RBC-Mag at the higher end of the normal
range (between 4.2 and 6.8 mg/dL to be about 6.0 ng/dL).
Mechanisms
There are at least 11 different types of magnesium that can be taken in supplement form with varying
bioavailability. Generally, organic salts of Mg have a higher solubility than inorganic salts and have
greater bioavailability. [151] Magnesium citrate is a widely used type of magnesium in salt form and is
often recommended to treat constipation; high doses may cause diarrhea and prolonged use should be
avoided. Magnesium oxide and magnesium citrate compounds, commonly prescribed by physicians,
have poor bioavailability. [152] Magnesium Malate, Taurate, Glycinate, and L-threonate have good
bioavailability and will readily increase RBC magnesium levels. Magnesium taurate and magnesium L-
threonate significantly increase magnesium levels in brain cells; hence they are used in the treatment of
depression and Alzheimer’s disease. [152,153]

High intakes of magnesium from dietary supplements and medications can cause diarrhea, nausea, and
abdominal cramping.

Methylene blue
Low Dose Methylene Blue (LDMB) is a therapeutic option in patients with brain fog and other
neurological symptoms; this can be combined with transcranial photobiomodulation.

10-30 mg daily. The optimal dose is highly individualized and each patient needs to find the right dose
for them.
It is important that patients and/or their healthcare providers purchase high-quality, impurity-free,
pharmaceutical-grade methylene blue. Patients may purchase a 1% methylene blue solution (e.g.
https://www.bphchem.com/product/methylene-blue-1-usp-grade-50-ml-1-drop-contains-0-5-mg-of-
methylene-blue/), MB in a powder form requiring reconstitution into a 1% solution (e.g. from CZTL at
https://cztl.bz/?ref=Lwr85 ) or MB Buccal Trouches (https://troscriptions.com/products/) (will cause
blue staining of mouth and teeth; trouches can be swallowed to avoid this effect).
A 1% methylene blue solution contains 10 mg MB in 1 ml solution (and 0.5 mg/drop). A 1% MB solution

is formulated by mixing 1 gram of methylene blue with 100 ml of water. Use a dropper bottle to
administer — 1 drop of 1% solution is approximately 0.5 mg of methylene blue).
Dosing of LDMB:
• Start with 5 mg (.5 ml) twice daily for the first week.
• Gradually increase the dosage every 2-3 days (guided by symptoms - i.e., improvement in
fatigue and/or cognitive improvement) until you reach a maximum of 30 mg (3 ml) per day.
• Take the 7th day off every week to allow the body to “reset”.
Mechanisms
Methylene blue (MB) has a number of biological properties that may be potentially beneficial in vaccine-
injured patients. MB induces mitophagy (mitochondrial autophagy) and has anti-inflammatory,
antioxidant, neuroprotective, and antiviral properties. [154,155] A study in 2013 found that methylene
blue-induced neuroprotection is mediated, at least in part, by macroautophagy through activation of
AMPK signaling. [156]
MB easily crosses the BBB and preferentially enters neuronal mitochondria. MB has high bioavailability
to the brain with brain tissue levels tenfold higher than serum levels. [157,158] Low-dose methylene
blue (LDMB) stimulates mitochondrial respiration by donating electrons to the electron transport chain.
MB can reroute electrons directly from complex I to complex III, avoiding electron leakage and
subsequent ROS production.
MB and photobiomodulation (PBM) have similar beneficial effects on mitochondrial function, oxidative
damage, and inflammation. Treatment with MB is therefore often combined with PBM therapy.
[159,160]. However, because PBM and MB exert beneficial effects through distinct mechanisms,
combining the use of these two therapies is expected to improve therapeutic outcomes synergistically.
Numerous studies indicate an improvement in brain mitochondrial function and neurological function
following treatment with MB and PBM for a spectrum of neurological diseases. [158,159,161]

LDMB will cause your urine to be blue or blue-green. Some patients may experience a Herx reaction. A
Herx reaction may cause fatigue, nausea, headache, or muscle pain. If you experience a Herx reaction,
stop the protocol for 48 hours and then resume again slowly.
DO NOT take MB if you are pregnant or breastfeeding.
MB is a potent monoamine oxidase inhibitor (MAOI) that, in conjunction with an SSRI, can potentiate
serotonin syndrome, a life-threatening medical emergency. This combination of medications is to be
strongly avoided. Do not take FLUVOXAMINE, FLUOEXETINE or BUPROPION or any other SSRI -NDRI
(norepinepine-Dopamine Reutake Inhibitor) with MB.
MB increases toxicity of hydrocodone bitartrate by increasing serotonin levels in the blood. This
combination should be avoided.
Individuals with glucose-6-phosphate dehydrogense deficiency (G6PD) should not be treated with MB as
it can cause hemolytic anemia.
Sunlight and Photobiomodulation (PBM)

Sunlight has great therapeutic powers. Our forefathers roamed the earth and were exposed to sunlight
on a daily basis, likely with profoundly important health benefits. [162]

We suggest that patients expose themselves to about 30 mins of midday sunshine whenever possible (at
least 3 times a week). A brisk midday walk is a viable alternative. When neither of these interventions is
feasible or practical, and in those who wish to avoid ultraviolet radiation exposure, patients can expose
themselves to red and NIR radiation emitted from LED panels.
Those interested in this therapy are recommended to read the book by Ari Whitten entitled “The
Ultimate Guide to Red Light Therapy.” [163]
A number of LED panels with multiple red and IR lights are commercially available (e.g.
https://mitoredlight.com/, https://hoogahealth.com/, https://platinumtherapylights.com/. The
disadvantage of LED panels is they do not mimic that of solar radiation as they deliver 1-10 nm wide
spiked emissions of red light at 660 nm and NIR-A at 830 nm. In contrast, ThermaLight® bulbs
(SaunaSpace® Saunas™) have a radiation spectrum closely resembling that of solar radiation, but
without UV radiation. About 39% of the emitted spectrum of the ThermaLight® bulb is NIR-A (the solar
spectrum has 41% IR-A) and about 41% of the radiation is in the IR-B range; part of IR-A and IR-B (1000-
3000 nm) contributes to the thermal effects of emitted radiation, which promotes induced
hyperthermia (sauna therapy) and is discussed below under “Other Potential Therapies”.
Mechanisms
PBM is referred to in the literature as low-level light therapy, red light therapy, and near-infrared light
therapy. The spectral radiance of solar radiation extends from 10 nm to about 3000 nm i.e., the
spectrum from ultraviolet (10-400 nm), visible (400-700 nm with red light 600-700 nm), near-infrared
radiation (750-1500 nm (NIR-A)) and mid-infrared radiation (1500- 3000 nm (NIR-B)).

Of all the wavelengths of sunlight, NIR-A radiation has the deepest penetration into tissues, being up to
23cm. NIR-A in the range of 1000 to 1500 nm is optimal for heating tissues. Indeed, during the 1918
influenza pandemic, “open-air treatment of influenzae” appeared to be the most effective treatment for
seriously ill patients. [164] The Surgeon-General of Massachusetts reported that “plenty of air and
sunshine” was highly effective for the treatment of influenzae pneumonia. He reported that “very little
medicine was given after the value of plenty of air and sunshine had been demonstrated.” Further, he
comments “from being discouraged, the medical staff became enthusiastic, and the patients were
treated with the confidence that at last something had been found which would give good results.”
A more recent large prospective study demonstrated that avoiding sun exposure is a risk factor for all-
cause mortality. [165] In this study, the mortality rate amongst avoiders of sun exposure was
approximately twofold higher compared with the highest sun exposure group. Apart from UV radiation
stimulating vitamin D synthesis, red and near-infrared (NIR) radiation have a profound effect on human
physiology, notably acting as a mitochondrial stimulant and increasing ATP production. [166]
The most well-studied mechanism of action of PBM centers around enhancing the activity of
cytochrome c oxidase, which is unit four of the mitochondrial respiratory chain, responsible for the final
reduction of oxygen to water. In addition, one of the most reproducible effects of PBM is an overall
reduction in inflammation. PBM has been shown to reduce markers of M1 phenotype in activated
macrophages. [166] Many reports have shown reductions in reactive nitrogen species and
prostaglandins in various animal models. In addition, PBM activates a wide range of transcription factors
leading to improved cell survival. It has also been suggested that NIR light increases the production of
melatonin in mitochondria. [167]
In an outstanding in vitro study, Aguida et al demonstrated that infrared light caused a marked
reduction in the TLR-4-dependent inflammatory response pathway in a human cell culture line. [168] In
this study, infrared light exposure resulted in a significant decline in NFkB and AP1 activity as well as a
marked decrease in the expression of proinflammatory genes. The increased body temperature induced
by NIR-A and NIR-B activates the production of heat shock proteins (which increase autophagy) as well
as essential cell stress survival pathways.
Emerging data suggest that transcranial PBM has beneficial effects in a range of neuro-psychiatric
diseases including stroke, traumatic brain injury, Alzheimer's disease, Parkinson’s disease, and
depression. [169-172] PBM has been suggested to have a role in the prevention and treatment of
COVID-19. [173] A recent double-blind, sham-controlled study using an LED device demonstrated a
marked improvement in the condition of hospitalized patients with acute COVID-19 infection. [174]
Resveratrol or a combination flavonoid

Resveratrol is a plant phytochemical (flavonoid) that has remarkable biological properties. [175-177]
Most importantly it activates autophagy. [178,179]

400-500 mg daily. Resveratrol may potentiate the effect of time restricted feeding (intermittent fasting)
in activating autophagy. Resveratrol should therefore be taken during fasting and not with a meal. For
acutely symptomatic patients, resveratrol in a dose of 500 mg twice daily is suggested. In recovered
patients and those on preventative/maintenance therapy, a dose of 400-500 mg/day should suffice.

Mechanisms
Resveratrol has anti-inflammatory, antiviral (SARS-CoV-2), antioxidant, and anticoagulant properties and
has beneficial effects on the microbiome. Resveratrol also binds to spike protein helping to promote
autophagy.
Quercetin, a plant flavonoid with many of the biological properties of resveratrol, acts synergistically
with resveratrol and increases the bioavailability of resveratrol. [180-182] Pterostilbene, is another plant
flavonoid similar to resveratrol in structure with similar biological properties. [183-185] However,
pterostilbene's unique structure makes it more oil-soluble than resveratrol, which increases its
absorption and cellular uptake while reducing the rate of elimination from the body. Research has
shown that pterostilbene has seven times the half-life of resveratrol and has greater bioactivity in
reducing the effects of oxidative stress. We, therefore, suggest a “high quality” combination supplement
with resveratrol and quercetin and ideally also containing pterostilbene.

Generally, the oral bioavailability of resveratrol is poor. [186] However, a bio-enhanced formulation
containing trans-resveratrol from Japanese Knotweed Root appears to have improved bioavailability.
The safety of these phytochemicals has not been determined in pregnancy and they should therefore be
avoided.
Due to the possible drug interaction between quercetin and ivermectin these drugs should not be taken
simultaneously (i.e., should be staggered morning and night).
The use of quercetin has rarely been associated with hypothyroidism. [187] The clinical impact of this
association may be limited to those individuals with pre-existent thyroid disease or those with
subclinical thyroidism. Quercetin should be used with caution in patients with hypothyroidism and TSH
levels should be monitored.
Probiotics/prebiotics
Patients with post-vaccine syndrome classically have a severe dysbiosis with loss of Bifidobacterium.
[188-190]

A no-sugar-added, Greek yogurt with both pre- and probiotics is recommended. Suggested probiotics
include Megasporebiotic (Microbiome labs), TrueBifidoPro (US Enzymes), and yourgutplus+. [191] In
addition, the use of Glucomannan (from Konjac root) and/or Chia seeds provide soluble and insoluble
fiber (prebiotic) required for the normalization of the microbiome. [297-299]

If patients have moderate to severe dysbiosis and/or small bowel bacterial overgrowth (SBIO) then
prebiotics may have the unwanted effect of ''feeding the bad bacteria" and contributing to worsening of
the dysbiosis. Probiotics alone and/or fermented foods are less likely to harbor and nourish commensal
and abnormal gut microbes. Depending on the brand, some pro/prebiotic products can be very high in
sugar, which promotes inflammation. Look for brands without added sugar and try to choose products
that are also gluten-free, casein-free, and soy free.

Adjunctive/Second-Line Therapies
(Listed in order of importance)
• Vitamin D (4000-5000 units/day) and Vitamin K2 (100 mcg/day); The dose of Vitamin D should
be adjusted according to the baseline Vitamin D level. However, a dose of 4000-5000 units/day
of Vitamin D, together with Vitamin K2 100 mcg/day is a reasonable starting dose.
• N-acetyl cysteine (NAC); 600-1500 mg/day [192-194] NAC is the precursor of reduced
glutathione. NAC penetrates cells where it is deacetylated to yield L-cysteine thereby promoting
GSH synthesis. [194] Based on a broad range of antioxidant, anti-inflammatory, and immune-
modulating mechanisms, the oral administration of NAC likely plays an adjuvant role in the
treatment of the vaccine injured. Several studies showed that NAC is well absorbed by the
intestine and that a supplementation with NAC is effective for increasing GSH levels.
Oral glutathione is poorly absorbed and is generally not recommended. [195,196] However,
acetyl glutathione is more lipophilic than glutathione, sufficiently so to be taken up intact by
cells, and has been shown to rapidly raise intracellular GSH levels. A combination supplement
that contains acetyl glutathione, NAC and Vitamin C may enhance the bioavailability of
glutathione. In addition, liposomal glutathione has been demonstrated to increase tissue levels,
antioxidant capacity and immune function. [197]
• Cardio Miracle™ and L-arginine/L-citrulline supplements. Cardio Miracle is a supplement with

over 50 ingredients formulated to increase nitric oxide (NO) production. The supplement
contains L-arginine, L-citrulline, Beetroot (high in dietary nitrates), L-Ornithine, CoQ10, as well as
a blend of fruit and vegetable phytonutrients. L-Arginine is the substrate used for NO production
by nitric oxide synthetase (NOS). [257] Patients with acute COVID-19 infection have been
demonstrated to have low plasma L-arginine levels. [258] In addition, COVID-19 syndromes are
characterized by suppressed endothelial nitric oxide synthase (eNOS) activity compounding the
deficiency of NO. [259;260] The spike protein itself may play a major role in inhibiting eNOS
activity. The NO deficiency is a major factor causing endothelial dysfunction and thrombotic
events. Furthermore, activation of the NO-cyclic GMP pathway has anti-inflammatory effects
modulating activated T cells, reducing cytokine release, and stimulating vascular repair. [261] In
addition, L-arginine itself is important for normal T cell function and macrophage M1-to-M2
switch. [257] It is likely that an L-arginine/L-citrulline supplement will have additive or
synergistic effects when combined with a phosphodiesterase-5 inhibitor. (see below). L-arginine
should likely be avoided in patients with active malignancies. [198,199]
• Omega-3 fatty acids; we suggest a combination of EPA/DHA with an initial dose of 1 g/day
(combined EPA and DHA) and increasing up to 4 g/day (of the active omega-3 fatty acids). The
omega-3 fatty acids have anti-inflammatory and cardioprotective effects and play an important
role in the resolution of inflammation by inducing resolvin production. [200,201] Furthermore,
omega-3 fatty acids are believed to afford potent vasculoprotective effects, by improving
endothelial function, limiting vascular inflammation, reducing thrombosis, and limiting reactive
oxygen species production. [202] Fish, particularly wild Atlantic (or Alaskan) salmon, are a good
source of omega-3 fatty acids. Omega-3 supplements include Vascepa™ (icosapent ethyl; an
ethyl ester of eicosapentaenoic acid [EPA]), Lovaza™ (a combination of ethyl esters of EPA and
docosahexaenoic acid [DHA]) as well as “regular fish oil supplements” containing a combination

of EPA/DHA. It is unclear if the reported cardiovascular and anti-inflammatory benefits of
omega-3 fatty acids are predominantly due to EPA (i.e., Pharma marketing) or the combination
of EPA and DHA. [203-210] However, it is now widely appreciated that ”EPA and DHA are
metabolized to different mediators and are equally important with respect to cardiovascular
protection (and inflammation).” [207] Based on this data we suggest a combination of EPA/DHA
with an initial dose of 1 g/day (combined EPA and DHA) and increasing up to 4 g/day (of the
active omega-3 fatty acids).
• Sildenafil with or without L-arginine-L-Citrulline [211-216]; Sildenafil doses titrated up from 25

to 100 mg 2-3 times daily with L-arginine/L-citrulline powder twice daily. May be helpful for
brain fog as well as microvascular disease with clotting and poor perfusion. It is noteworthy that
curcumin, resveratrol, EGGG, and valproic acid all potentiate phosphodiesterase 5 (PDE5)
inhibitors.
• Nigella sativa; 200-500 mg encapsulated oil twice daily. Nigella sativa is a small shrub native to
Southern Europe, North Africa, and Southeast Asia. The seeds and oil of Nigella sativa have been
used as a medical agent for thousands of years. The most important active component is
thymohydroquinone. Nigella sativa has antibacterial, antifungal, antiviral (SARS-CoV-2), anti-
inflammatory, antioxidant, and immunomodulatory properties. [217,218] A dose of 200-500 mg
twice daily of the encapsulated oil is suggested. [217-220] It should be noted that
thymohydroquinone decreases the absorption of cyclosporine and phenytoin. Patients taking
these drugs should, therefore, avoid taking Nigella sativa. [221] Furthermore, two cases of
serotonin syndrome have been reported in patients taking Nigella sativa who underwent
general anesthesia (probable interaction with opiates). [222]
• Vitamin C; 1000 mg orally two to three times a day. Vitamin C has important anti-inflammatory,
antioxidant, and immune-enhancing properties, including increased synthesis of type I
interferons. [223-227] Avoid in patients with a history of kidney stones. Oral Vitamin C helps
promote the growth of protective bacterial populations in the microbiome.
• Spermidine; 1000-2000 mg (wheat germ extract) daily. Spermidine is a naturally occurring

polyamine that, like resveratrol, has anti-inflammatory and antioxidant properties. It preserves
mitochondrial function and has been shown to reduce cardiovascular disease and all-cause
mortality and prolong lifespan. [228,229] Furthermore, like resveratrol, spermidine promotes
autophagy. However, resveratrol and spermidine activate autophagy via different metabolic
pathways and are therefore likely to have additive or synergistic effects. [230] Wheatgerm,
mushrooms, grapefruit, apples, and mango are high natural sources of spermidine. [231]
Wheatgerm supplements contain high amounts of spermidine with good bioavailability. A dose
of 1000-2000 mg wheat germ extract daily is suggested. Cancer cells are reported to have
dysregulated polyamine metabolism and spermidine is therefore best avoided in patients with a
known malignancy. [232] In addition, spermidine should be avoided in men over the age of 60
who are at high risk of an ischemic stroke. [233]
• Non-invasive brain stimulation (NIBS), using transcranial direct current stimulation or

transcranial magnetic stimulation, has been demonstrated to improve cognitive function in
patients with long COVID as well as other neurological diseases. [234-241] NIBS is painless,
extremely safe, and easy to administer. NIBS is a recognized therapy offered by many Physical
Medicine and Rehabilitation Centers (e.g., see

https://www.hopkinsmedicine.org/physical_medicine_rehabilitation/services/programs/brain-
stimulation/treatment.html). Patients may also purchase an FDA-approved device for home use
(e.g., https://www.fisherwallace.com)
• Intravenous Vitamin C; 25 g weekly, together with oral Vitamin C 1000 mg (1 gram) 2-3 times
per day. High-dose IV vitamin C is “caustic” to the veins and should be given slowly over 2-4
hours. Furthermore, to assess patient tolerability the initial dose should be between 7.5-15 g.
Total daily doses of 8-12 g have been well-tolerated, however, chronic high doses have been
associated with the development of kidney stones, so the duration of therapy should be limited.
[103-108] Wean IV Vitamin C as tolerated.
• Behavioral modification, relaxation therapy, mindfulness therapy [242], and psychological

support may help improve patients’ overall well-being and mental health. [243] Suicide is a real
problem in the vaccine-injured patient. Support groups and consultation with mental health
professionals are important. Tai Chi, a health-promoting form of traditional Chinese martial art,
has been shown to be beneficial for preventing and treating diseases including long COVID.
[244,245] Yoga has immunomodulating properties that may be beneficial in vaccine-injured
patients. [246]
Third Line Therapies

• Hyperbaric oxygen therapy (HBOT) [247-255]; HBOT has potent anti-inflammatory properties,
decreasing pro-inflammatory cytokines while increasing IL-10. Furthermore, HBOT polarizes
macrophages toward the M2 phenotype and improves mitochondrial function. Surprisingly, it is
the increased pressure, rather than the increase in the concentration of dissolved oxygen, that
appears to mediate these effects. HBOT is delivered at varying pressures, both with and without
oxygen. The addition of oxygen increases the clinical response. Maximal clinical response is
achieved via the use of high-pressure chambers (typically reaching 2.4 ATM) with 100% oxygen
for 60-90 minutes. If HBOT is delivered using lower pressure chambers (less than 1.5 ATM)
without supplemental oxygen, the clinical response, although present, is significantly less such
that a higher number of sessions will be needed to reach a clinical plateau.
Zilberman-Itskovich et al performed a randomized, sham-controlled, double-blind trial that

evaluated the effect of HBOT in 73 patients with long COVID. [256] Both HBOT and sham
patients received 40 daily sessions (five times a week) in a multi-place chamber. The HBOT
protocol included breathing 100% oxygen by mask at 2 ATM for 90 minutes. In the HBOT group,
there was a significant improvement in global cognitive function, attention, and executive
function as well as an improvement in the energy domain, psychiatric symptoms, and pain level.
Clinical outcomes were associated with significant improvement in brain MRI perfusion and
microstructural changes. In general, the duration of treatment of HBOT should be based on
clinical response and continued for at least 40 sessions and until the benefit has plateaued. If no
benefit is evident clinically after 10 sessions, then HBOT should be considered a therapeutic
failure. This therapy is limited by logistical issues and cost. A number of companies offer to rent
portable, low-pressure chambers with the option to purchase
(https://www.oxyhealth.com/vitaeris-320.html, https://summit-to-sea.com/, https://www.aha-
hyperbarics.com/)

• Low Magnitude Mechanical Stimulation (LMMS or Whole-Body Vibration). Low-magnitude (0.3-
0.4G), high-frequency (32-40 Hz) mechanical stimulation has been demonstrated to increase
bone density as well as indices of general well-being in patients with a variety of medical
disorders. [257] It is postulated that this intervention recruits bone marrow stem cells in
addition to having metabolic and immunologic effects. In humans, low-magnitude acceleration
is applied through the feet by standing on a platform oscillating at relatively high resonant
frequency. These parameters are very safe, painless, and easy to administer. This therapy is
offered by Physical Medicine and Rehabilitation Centers, or a device may be purchased for
home use https://www.juvent.com/health/) similarly with noninvasive brain stimulation (NIBS).
• “Mitochondrial energy optimizer” with pyrroloquinoline quinone, glycophospholipids, CoQ10,

NADH, and other nutrients (e.g., Life Extension Energy Optimizer, Restorative Solutions
Mitochondrial Nutrition PQQ, Researched Nutritionals ATP 360® and ATP Fuel® and Pure
Encapsulations Mitochondria-ATP) [258-264]
• Hydroxychloroquine (HCQ); 200 mg twice daily for 1-2 weeks, then reduce as tolerated to 200
mg/day. HCQ is a potent immunomodulating agent and is considered the drug of choice for
systemic lupus erythematosus (SLE), where it has been demonstrated to reduce mortality from
this disease. Thus, in patients with positive autoantibodies or where autoimmunity is suspected
to be a prominent underlying mechanism, HCQ should be considered earlier. Further, it should
be noted that SLE and post-vaccine syndrome have many features in common. HCQ is safe in
pregnancy; indeed, this drug has been used to treat preeclampsia. [265-269] With long-term
usage, the dose should be reduced (100 or 150mg/day) in patients weighing less than 61 kg (135
lbs.). It should be noted that HCQ will limit the effectiveness of intermittent fasting.
• Low dose corticosteroid; 10-15 mg/day prednisone for 3 weeks. Taper to 10 mg/day and then 5
mg/day, as tolerated.
Patients with elevated homocysteine levels

Patients with elevated homocysteine levels may benefit from treatment with 800 ug of 5-methyl
tetrahydrofolate (5-MTHF), the most biologically active form of folic acid. [270] Supplementation with
folic acid alone will paradoxically increase homocysteine levels, particularly in patients with MTHFR
polymorphism. [270] In addition, B complex vitamins containing B2 (riboflavin) and Vitamin B6,
magnesium, and Vitamin D should be added. [62]
Other Potential Treatments

(Require further evaluation)
• Plasmapheresis. Plasmapheresis improves systemic cytokine levels, coagulopathy, and immune

responsiveness in patients with severe COVID with a potential mortality benefit. [271-278]
Kiprov, et. al. have published a case report of a dramatic clinical improvement in a patient with
long COVID. [279] In this report, the patient’s markers of inflammatory macrophages
diminished, and markers of lymphocytes, including natural killer cells and cytotoxic CD8 T-cells,
increased; in addition, circulating inflammatory proteins diminished. Furthermore, it is likely
that plasmapheresis removes autoantibodies and improves the coagulopathy of these patients.
We are aware of anecdotal reports of marked improvement in neurological symptoms,

especially SFN and brain fog in vaccine-injured patients treated with this therapeutic modality.
However, this is a limited and expensive resource that, in itself, is not without complications.
Furthermore, the durability of the clinical response needs to be determined. While
plasmapheresis/plasma exchange is a therapeutic option for the severely neurologically
impaired patient following vaccination, additional data is required before this modality can be
widely recommended.
• Valproic acid [280,281]; Depakote, 250mg 2-3 times daily. Valproic acid has anti-inflammatory
effects and polarizes macrophages towards an M2 phenotype. [282] Histone deacetylase (HDAC)
inhibitors are being studied for neural regeneration. In addition, valproic acid has important
anticoagulant and anti-platelet effects [283] and is an inducer of heat shock proteins. [284]
Valproic acid may be helpful for neurological symptoms. Treatment should be limited to less
than 6 to 9 months due to the concern for the loss of brain volume particularly in those patients
with cognitive dysfunction. [285] In a cerebral ischemia/hypoxia model resveratrol markedly
enhanced the neuroprotective effects of valproic acid. [286] Furthermore, resveratrol has been
reported to reverse the toxicity of valproic acid, [287,288]. These data suggest that resveratrol
(in a dose of 500 mg – 1000 mg twice daily) should be recommended in patients prescribed
valproic acid.
• Induced hyperthermia and Cold Hydrotherapy. The role of sauna bathing and cold therapy
(cold showers, cold baths) in patients with long COVID and the vaccine-injured is unknown.
[289,290] Regular sauna bathing has been proven to reduce all-cause and cardiovascular
mortality, prolong the lifespan, improve exercise performance, and improve the outcome of
patients with neuropsychiatric disease. [291-295] Induced hyperthermia increases the
expression of heat shock proteins, which activates autophagy. In addition, heat therapy
increases the expression of cell stress pathways, has antioxidant and anti-inflammatory effects,
and improves mitochondrial function. [289] Sauna bathing has very similar physiologic effects to
that of aerobic exercise (increase heart rate, stroke volume, and cardiac output). [296,297] As
patients with long COVID and the vaccine-injured are exercise intolerant (they cannot increase
cardiac output) [143] sauna bathing may be poorly tolerated. However, sauna bathing and
induced hyperthermia have been shown to improve endothelial and cardiac function in patients
with chronic heart failure. [298] Furthermore a recent meta-analysis reported that sauna
bathing improved cardiac function in patients with chronic heart failure. [299] Waon therapy
(infrared dry sauna) has shown promising results in patients with chronic fatigue syndrome.
[300,301] Patients interested in sauna bathing should determine their tolerance to short
sessions (5-10 mins) and increase the duration as tolerated (up to 20 minutes) three to four
times a week. Similarly, the role of cold therapy in the vaccine-injured is unknown; patients
should similarly determine their tolerance to this treatment approach. [302,303]
• Pentoxifylline (PTX); PTX ER, 400 mg three times daily, should be considered in those patients
with severe microcirculatory disturbances. PTX is a non-selective phosphodiesterase drug that
has anti-inflammatory and antioxidant effects. [224] In addition, PTX improves red blood cell
deformability and reduces blood viscosity, so can mitigate the hyper-viscosity and RBCs hyper-
aggregation, which is linked with the development of coagulopathy in the vaccine injured.
• Maraviroc; 300 mg orally twice daily. If 6 to 8 weeks have elapsed and significant symptoms
persist despite the above therapies, this drug can be considered. Note Maraviroc can be
expensive and has a risk of significant side effects and drug interactions. Maraviroc is a C-C

chemokine receptor type 5 (CCR5) antagonist. While many long COVID and post-vaccine patients
have been treated with Maraviroc, the role of this drug requires further evaluation. [304]
• Sulforaphane (broccoli sprout powder) 500 mcg – 1g twice a day. While sulforaphane has many
potential benefits in patients with COVID, [305-307] long COVID and post-vaccine syndrome,
there is limited clinical data to support this intervention. Sulforaphane has immunomodulatory
effects by targeting monocytes/macrophages, suggesting a benefit in chronic inflammatory
conditions. [305-307] Sulforaphane is a beneficial supplement that may be useful for reducing
microglial-mediated neuroinflammation and oxidative stress. In addition, as has been well-
popularized, sulforaphane has an important role in cancer prophylaxis. The pharmacology and
optimal dosing of sulforaphane are complex. Sulforaphane itself is unstable. The supplement
should contain the two precursors, glucoraphanin and myrosinase, which react when the
supplement is consumed. Broccoli “extracts” are produced in a way that completely destroys
the activity of the myrosinase enzyme. As such, these extracts are incapable of producing
sulforaphane when consumed in a supplement or food. [308,309] We recommend a 100%
whole broccoli sprout powder, which maximally retains both glucoraphanin and myrosinase
whilst, at the same time, deactivating the inhibitors.
• Dandelion (Taraxacum officinale). The root, flower, and leaves of dandelion contain an array of
phytochemicals that have anti-inflammatory, antioxidant, hypolipidemic, antimicrobial, and
anticoagulant properties. [310,311] It is widely reported that dandelion is effective for
‘detoxifying’ spike protein. An in vitro study demonstrated that a dandelion leaf extract altered
the binding of SARS-CoV-2 spike protein to the ACE receptor. [312] It would appear that this
effect was due to alterations (binding) of the ACE-2 receptor rather than binding to the spike
protein. It, therefore, remains unclear whether dandelion extract actually binds to the spike
protein and would potentiate clearance of this protein. The European Scientific Cooperative on
Phytotherapy recommends a dose of 4-10 g TID (20-30mg/ml in hot water). [313] It should be
noted that Dandelion extract is considered contraindicated in those with liver and biliary
disease, bile duct obstruction, gallstones, cholangitis, and active peptic ulcer. [313] Furthermore
dandelion is rich in potassium and should be used cautiously in patients with kidney failure.
• VEDICINALS® 9; a unique phytopharmaceutical-based therapeutic suspension that consists of

nine bioactive compounds with antiviral, anti-inflammatory, immune-modulatory, antipyretic,
and analgesic properties. The compounds include Baicalin, Quercetin, Luteolin, Rutin,
Hesperidin, Curcumin, Epigallocatechin Gallate, Piperine, and Glycyrrhizin.
(https://www.vedicinals.com/vedicinals-9/). A number of these compounds are included in our
protocol and the additional benefit of this 9 phytopharmaceutical combination over more
widely available flavonoid combinations is unknown. [314]
• C60 or C60 fullerenes [315,316]; C60, short for Carbon 60, is composed of 60 carbon atoms
forming something that looks like a hollow soccer ball and is considered as a “free radical
sponge.” C60 is considered the single most powerful antioxidant ever discovered. Robert Curl,
Harold Kroto, and Richard Smalley were awarded the Nobel Prize for chemistry in 1996 for its
discovery.
• Intravenous immunoglobulin (IVIG) treatment; The role of IVIG in the treatment of the vaccine
injured is unclear. The response to IVIG in the general population of vaccine-injured patients is
mixed, with very few showing long-term improvement. Many patients who report an initial

improvement will relapse in 2 to 3 weeks. Other patients report no benefit, while some appear
worsened. Due to the presence of non-neutralizing anti-SARS-CoV-2 antibodies and anti-ACE-2
antibodies, etc., the real possibility exists that IVIG will cause antibody-dependent immune
enhancement (ADE) with a severe exacerbation of symptoms.
IVIG is, however, recommended in specific autoimmune syndromes, which include Guillain Barré
Syndrome, transverse myelitis, and immune thrombocytopenia. These patients should
concomitantly be treated with the core immune-modulating therapies. IVIG proved to be
ineffective in an RCT that enrolled patients with small fiber neuropathy. [317]
The fact that many patients report an initial response to IVIG supports the notion that many
aspects of this disease are due to autoantibodies. IVIG will remove preformed antibodies, but
they do not prevent the B cells from ongoing antibody production; hence the response is likely
to be short-lived, and interventions that limit the production of autoantibodies are therefore
required (core immune-modulating therapies).
• Immunosuppressive therapies; As a rule, immunosuppressive therapy should be avoided, as

these drugs may exacerbate the immune dysfunction in vaccine-injured patients and prevent
the restoration of immune homeostasis. A trial of immunosuppressive therapy may be indicated
in patients with an established autoimmune syndrome who have failed other therapeutic
interventions.

Disease-Specific Therapeutic Adjuncts
Small fiber neuropathy (SFN)/autonomic neuropathy
• Low-dose naltrexone (LDN) appears to play a pivotal role in the treatment of SFN.
• Tricyclic antidepressants (start at a low dose and increase as tolerated)
• Gabapentin: 300 mg twice daily and increase as tolerated
• Alpha lipoic acid; 600 mg/day (alpha-lipoic acid is an inducer of heat shock proteins). [318]
• POTS – ensure sufficient hydration and consider the use of compression stockings or abdominal
binders
• POTS – Clonidine; 0.1 mg twice daily as tolerated
• POTS – Fludrocortisone; 0.1 to 0.2 mg/day or licorice root (has glycyrrhizinic acid, an
aldosterone-like compound).
• POTS – midodrine; 5-10 mg three times daily
• Whole-body vibration therapy has been shown to improve symptoms of small fiber neuropathy.
[319,320]
• A trial of hyperbaric oxygen therapy (HBOT).
• Zinc; 25 mg daily (elemental zinc) together with the zinc ionophore quercetin. SFN is an
autoimmune disease; zinc deficiency has been associated with the development of autoimmune
diseases. [321]
• It should be noted that the diagnosis of small fiber neuropathy/autonomic neuropathy is a
clinical diagnosis. [47-54] Complex and expensive tests are NOT required to make this diagnosis.
It should be noted that SFN is closely associated with multiple autoantibodies. Testing for these
autoantibodies serves no useful clinical purpose as it does not change the treatment plan.
Generalized neurologic symptoms/“brain fog”/fatigue/visual symptoms

• LDN appears to play a pivotal role in the treatment of many neurological symptoms
• Methylene blue (as indicated above) and photobiomodulation
• Nigella Sativa; 200-500 mg twice daily.
• Non-invasive brain stimulation (NIBS) should be considered in patients with “brain fog,” memory
disturbances, and as well as other cognitive issues.
• Bupropion, a norepinephrine-dopamine reuptake inhibitor has been demonstrated to improve
fatigue and “brain-fog” in patients with both cancer and non-cancer related fatigue.[316;317]
The suggested doe is 150 mg extended-release tablet daily. After a month the dose can be
cautiously increased to 300 mg daily. Bupropion is CONTRAINDICATED in combination with
methylene blue.
• Intranasal oxytocin. Oxytocin is a nonapeptide produced in the hypothalamus, acting as a
neuropeptide in different brain areas (most notably the amygdala and hippocampus) and as a
hormone and paracrine substance in peripheral organs. [322-324] Oxytocin has colloquially been
referred to as the “love hormone’’, given its role in social interaction and bonding. [325]
Oxytocin has powerful anti-inflammatory and immunomodulating properties and may play an
important role in minimizing neuro-inflammation. [184-186] In addition, oxytocin has been
demonstrated to stimulate neuronal growth [323] Oxytocin plays an important role in
modulating the stress response. [326] Oxytocin has also been reported to have a role in the
prevention and treatment of migraine. [327,328] The nasal route appears to be the preferred
mode of administration. Martins et al performed a dose-finding study in healthy human
volunteers. [187] These authors measured changes in amygdala blood flow and demonstrated

an inverse dose-response curve, with lower doses resulting in a greater increase in blood flow.
They report the optimal dose as being between 9-18 IU. This suggests that one to two puffs to
each nostril (4 IU per puff) two times a day may be optimal (total dosage of 16-32 IU per day).
Oxytocin must be avoided in pregnancy. Oxytocin nasal spray should be compounded at 12 to
15 units/0.1ml (spray) and administered at onset aggressively to upregulate receptors at 2
sprays each nostril BID (8-sprays per day) for the first week and then maintenance at 2 sprays
ea. nostril (4/d) once daily. [329] Oxytocin can also be delivered via SL liquid or via lozenge.
• Spermidine and Resveratrol. Experimental studies have demonstrated that spermidine reduces
neuroinflammation, reduces accumulation of amyloid protein, and improves cognitive function.
[330,331] Similarly, resveratrol has been shown to be useful in the prevention and treatment of
Alzheimer’s disease. [179]
• Valproic acid and pentoxifylline may be of value in these patients.
• Fluvoxamine: Start on a low dose of 12.5 mg/day and increase slowly as tolerated. Some
patients report a significant improvement with fluvoxamine while other patients appear to
tolerate this drug poorly. Fluoxetine 20 mg/day is an alternative, as are tricyclic anti-depressants
(see section on Depression below).
• These symptoms may be mediated by Mast Cell Activation Syndrome (MCAS); see specific
treatment below.
Depression
• Depression is a serious problem in long COVID and post-vaccine patients and, unfortunately, suicide
is not uncommon. [332-334] Patients with a history of depression and/or those taking SSRI
medications appear to be at particular risk of severe depression.
• Patients with depression are best managed by mental health providers with expertise in this area.
Long-term SSRI medications are generally not recommended due to the long-term effects of these
drugs on serotonin receptors, intracellular messenger pathways as well genetic and epigenetic
effects. [335,336] It should be noted that most SSRI/SNRI agents, but notably sertraline,
fluvoxamine, paroxetine, venlafaxine, and duloxetine are associated with severe anxiety which may
progress to mania, self-inflicted harm, suicide, anger outbursts, physical violence, homicidal
thoughts, and homicide. [337-340] Patients who are treated with antidepressant agents, therefore,
require close monitoring for the development of these serious adverse reactions.
• There appears to be an interaction between vaccination, COVID-19, zinc levels, and depression.
[341-344] COVID-19 infection and COVID vaccines may lead to low zinc levels. Zinc deficiency is
associated with an increased risk of depression. Treatment with zinc has been shown to have
antidepressant effects and to act synergistically with SSRI medication. [345] 25 mg zinc daily
(elemental), together with the zinc ionophore quercetin is therefore suggested. [344]
• Non-invasive brain stimulation (NIBS) using transcranial direct current stimulation or transcranial
magnetic stimulation has been demonstrated to be highly effective in the treatment of depression.
[346-350] Indeed, The Fisher Wallace Stimulator® is FDA approved for the treatment of depression,
anxiety, and insomnia. NIBS is painless, extremely safe, and easy to administer. NIBS is a recognized
therapy offered by many Physical Medicine and Rehabilitation Centers. Patients may also purchase
an FDA-approved device for home use (https://www.fisherwallace.com/).
• Methylene blue (dose as indicated above) has been proven to be beneficial in patients with
depression.[351,352] Do NOT TAKE FLUVOXAMINE, FLUOXETINE, BUPROPION or any other SSRI-
NDRI with MB.
• Photobiomodulation and sauna bathing have been shown to be highly effective for the treatment of
depression. [294,353-355]

• In experimental models, Nigella sativa has been shown to have a role in the treatment of
depression. [356]
• Altered gut flora/dysbiosis has been linked to anxiety and depression and the use of probiotics has
been associated with an improvement in mood. [357-361] Since infection with SARS-CoV-2 and
those who have been vaccinated have dysbiosis the use of pre- and probiotics are suggested.
[189,190,362,363] Unsweetened Greek yogurt with pre and probiotics is recommended. Suggested
probiotics include Megasporebiotic (Microbiome labs) and TrueBifidoPro (US Enzymes) and
yourgutplus+. [191] In addition, the use of Glucomannan (from Konjac root) and/or Chia seeds
provide soluble and insoluble fiber required for the normalization of the microbiome. [364-366] If
patients have moderate to severe dysbiosis and/or small bowel bacterial overgrowth (SBIO) then
prebiotics may have the unwanted effect of ''feeding the bad bacteria" and contributing to
worsening of the dysbiosis. Probiotics alone and/or fermented foods are less likely to harbor and
nourish commensal and abnormal gut microbes.
Patients with elevated DIC and those with evidence of thrombosis

• See section on anticoagulation. The patient’s risk of bleeding needs to be assessed as this will
determine the aggressiveness of anticoagulation.
• These patients should be treated with a DOAC or coumadin for at least three months and then
reevaluated for ongoing anticoagulation.
• Patients should continue ASA 81 mg/day unless at high risk of bleeding.
• Nattokinase 100-1220mg twice daily is suggested unless at high risk of bleeding.
• Triple anticoagulation should be considered in select patients. [96] Treat no longer than one
month. Triple anticoagulation increases the risk of serious bleeding; patients should be
counseled regarding this complication.
• In those patients with marked microvascular disease/thrombosis, the combination of
pentoxifylline and sildenafil should be given a therapeutic trial. [367,368]
Vaccine-induced myocarditis/pericarditis
• ACE inhibitor/ARB, together with carvedilol as tolerated to prevent/limit progressive decline in
cardiac function.
• Colchicine in patients with pericarditis – 0.6 mg/day orally; increase to 0.6 mg twice daily if
required. Reduce dose if patients develop diarrhea. Monitor white blood cell count. Decrease
dose with renal impairment.
• Magnesium to reduce the risk of serious arrhythmias (see dosing above).
• Coenzyme Q (CoQ) 200-400mg/day. [369-372]
• Omega-3 fatty acids – EPA/DHA 2-4 g/day [373-375] Increase dose slowly as tolerated.
• Resveratrol/flavanoid combination for its anti-inflammatory and antioxidant properties.
• Referral to a cardiologist or ER in case of persistent chest pain or other signs and symptoms of
cardiac events are observed.
Herpes virus reactivation syndrome

• Valtrex; 500-1000 mg twice daily for 7-10 days (acyclovir is an alternative). [376]
• Spironolactone 50-100 mg daily [377]. Spironolactone has antiviral properties against Epstein
Barr Virus by inhibiting viral capsid antigen synthesis and capsid formation. Spironolactone likely
has antiviral effects against other Herpes viruses.
• L-Lysine; 1000 mg twice daily [378,379]

• Valproic acid; Depakote, 250 mg 2-3 times daily. Valproic acid has activity against HSV-1, HSV-2,
HZV, CMV, and EBV. [380-382]
• Zinc 40 mg daily [383,384]
• Quercetin “Phytosome” 500 mg twice daily (antiviral properties and a Zinc ionophore) [385]
Tinnitus
• This a frequent and disabling complication reported in post-vaccine syndrome.
• Tinnitus refers to the sensation of sound in the absence of a corresponding external acoustic
stimulus and can, therefore, be classified as a phantom phenomenon. Tinnitus sensations are
usually of an unformed acoustic nature such as buzzing, hissing, or ringing. Tinnitus can be
localized unilaterally or bilaterally, but it can also be described to emerge within the head. [386]
• Ideally, patients should be evaluated by an ENT specialist or audiologist to exclude underlying
disorders.
• A number of treatment approaches exist to manage this disabling disease including: [386-388]
o Cognitive behavioral therapy [389]
o Specialized therapy including tinnitus retraining therapy, hearing aids, sound therapy,
auditory perceptual training, and repetitive transcranial magnetic stimulation. [386]
o A number of pharmacologic agents have been used to treat tinnitus. Anticonvulsants
including carbamazepine have generally been disappointing. The following drugs have
shown some clinical benefit.
• Tricyclic antidepressant agents particularly nortriptyline and amitriptyline.
[390,391] In addition, the SSRI sertraline has shown some efficacy. [392]
• Clonazepam and or other benzodiazepines. These drugs may provide temporary
relief, however, due to issues of dependence, long-term use is not
recommended. [393]
• Melatonin slow release 2-6 mg at bedtime. [394]
• Oxytocin nasal spray. Oxytocin acts as a neurotransmitter affecting several neural circuits,
particularly in the hypothalamus and amygdala. [324] Oxytocin nasal spray has shown promising
results for the treatment of tinnitus (one puff to each puff nostril two times a day; a total dosage
of 16 IU per day). [395] Oxytocin must be avoided in pregnancy. Oxytocin nasal spray should be
compounded at 12 to 15 units/0.1ml (spray) and administered at onset aggressively to
upregulate receptors at 2 sprays each nostril BID (8-sprays per day) for the first week and then
maintenance at 2 sprays ea. nostril (4/d) once daily. [329] Oxytocin can also be delivered via SL
liquid or via lozenge.
• Non-invasive brain stimulation (NIBS) has proven to be effective in controlling treatment-
resistant tinnitus. [240,241]
Ageusia and anosmia (Loss of taste and smell)

• Loss of smell and taste is a troubling symptom in post-COVID patients and in the vaccine injured.
The loss of taste usually follows the loss of smell. Multiple mechanisms may explain the loss of
smell including direct injury to the olfactory bulb. [396] Anosmia is a particularly difficult
condition to treat. [397]
• Oxytocin nasal spray. Oxytocin receptors are highly expressed on olfactory neurons as well as
limbic structures. Oxytocin nasal spray has been demonstrated to improve the sense of smell in
patients with schizophrenia. A dose of one puff in each nostril two times a day for a total dosage
of 16 IU per day is suggested. [398] Oxytocin must be avoided in pregnancy.

• Olfactory training appears to be a promising therapy for patients with post viral olfactory loss to
partly regain their sense of smell. [399]
• Nasal corticosteroids appear ineffective and are not recommended for the use of anosmia. [400]
Bell’s palsy/facial paresthesia/visual issues

• Low-dose naltrexone. Begin with 1 mg/day and increase to 4.5 mg/day as required. May take 2-
3 months for full effect.
• Low dose corticosteroid: 10-15 mg/day prednisone for 3 weeks. Taper to 10 mg/day and then 5
mg/day as tolerated.
• Reduced workload, stress, and light exercises for a couple of months.
Patients with new onset allergic diathesis/features of Mast Cell Activation Syndrome
(MCAS)
• The novel flavonoid luteolin is reported to be a potent mast cell inhibitor. [401-404] Luteolin 20-
100 mg/day is suggested.
• Turmeric (curcumin); 500 mg/day. Curcumin has been reported to block H1 and H2 receptors
and to limit mast cell degranulation. [405,406] Curcumin has low solubility in water and is poorly
absorbed by the body; [407] consequently, it is traditionally taken with full-fat milk and black
pepper, which enhance its absorption. Nano-curcumin preparations or formulations designed to
enhance absorption are encouraged. [408-411]
• H1 receptor blockers. Loratadine 10 mg/day, Cetirizine 5-10 mg/day, Fexofenadine 180 mg/day.
• H2 receptor blockers. Famotidine 20 mg twice daily as tolerated. [412]
• Montelukast 10 mg/day. Caution as may cause depression in some patients. The efficacy of
montelukast as a “mast cell stabilizer’ has been questioned. [55]
• Ketotifen. 1 mg in 5 ml. Start with 0.5 ml at night. Once they get used to it, as it has a strong
hypnotic effect, increase by 0.5ml increments up to 5ml. Some patients can increase up to 10 ml
daily (1 mg BID). Ketotifen has antihistamine effects and is a mast cell stabilizer. Ketotifen may
be particularly useful in patients with GI hypersensitivity. [413,414]
• Vitamin C; 1000 mg twice daily. Vitamin C is strongly recommended for allergic conditions and
MCAS. Vitamin C modulates immune cell function and is a potent histamine inhibitor.
• Low histamine diet.
Alopecia (hair loss)

Three types of alopecia have been described in connection with COVID-19 infection, long COVID, and
post-vaccine syndrome. [415]
• Androgenetic alopecia (worsening of male pattern baldness)
• Alopecia areata, an autoimmune disorder that usually results in unpredictable, patchy hair loss.
In most cases, hair falls out in small patches around the size of a quarter. There is currently no
cure for alopecia areata; referral to a dermatologist is suggested. Preliminary research in
animals has found that quercetin can protect against the progression of alopecia areata and may
promote hair regrowth. [416,417]
• Telogen effluvium, which results in temporary thinning of the hair, particularly on the scalp.
Telogen effluvium is a reversible condition in which hair falls out after a stressful experience.
The stress pushes large numbers of hair follicles into a resting phase. Within a few months,
those hairs can fall out. This condition occurs predominantly in females and may be related to
increased expression of pro-inflammatory mediators. No specific treatment is required, as the
hair will usually grow back.

• Photobiomodulation treatments appear to be very effective in inducing hair regrowth. [418,419]
• Nutritional supplements containing omega-3 fatty acids (Vascepa), vitamin D, vitamin C, and zinc
are useful adjuncts to promote hair regrowth. [420-422]
• Topical minoxidil may promote hair regrowth. [423] Finasteride 2.5 mg daily is an option in both
men and women; [424] consult with a dermatologist and treatment for less than 1 year is
generally recommended.
• Topical valproic acid has been shown to stimulate hair regrowth. [425,426]

References
1. Blaylock RL. COVID Update: What is the truth? Surgical Neurology International 2022; 13.
2. Rose J. A report on the U.S. Vaccine Adverse Events Reporting System (VAERS) of the COVID-19
messenger ribonucleic acid 9mRNA) biologicals. Science, Public Health Policy, and Law 2021;
2:59-80.
3. Neil M, Fenton N, Smalley J et al. Latest statistics on England mortality data suggest systematic
mis-categorisation of vaccine status and uncertain effectiveness of Covid-19 vaccination.
Research Gate 2021.
4. Dickerman BA, Madenci AL, Gerlovin H et al. Comparative safety of BNT162b2 and mRNA-1273
vaccines in a Nationwide Cohort of US veterans. JAMA Intern Med 2022; 182:739-46.
5. Colunga Biancatelli RM, Solopov P, Sharlow E et al. The SARS-CoV-2 spike protein subunit 1
induces COVID-19 like acute lung injury in K18-hACE2 transgenic mice and barrier dysfunction in
human endothelial cells. Am J Physiol Lung Cell Mol Physiol 2021; 321:L477-L484.
6. Marik P, Iglesias J, Varon J et al. A Scoping Review of the pathophysiology of COVID-19.
International Journal of Immunopathology and Pharmacology 2021.
7. Seneff S, Nigh G, Kyriakopoulos AM et al. Innate immune suppression by SARS-C-V-2 mRNA
vaccinations: The role of G-quadruplexes, exosomes and microRNAs. Food & Chemical
Toxicology 2022; 164:113008.
8. Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: Theorectical, clinical and
practical aspects of anti-polyethylene glycol antibodies. ASC Nano 2021; 15:14022-48.
9. Mohamed M, Lila AS, Shimizu T et al. PEGylated liposomes: immunological responses. Science
and Technology of Advanced Materials 2019; 20:710-724.
10. Hamad I, Hunter AC, Szebeni J et al. Poly (ethylene glycol)s generate complement activation
products in human serum through increased alternative pathway turnover and a MASP-2
dependnet process. Molecular Immunology 2008; 46:225-32.
11. Seneff S, Nigh G. Worse than the disease? Reviewing some possible unintended consequences
of the mRNA vavvines against COVID-19. International Journal of Vaccine Theory, Practice, and
Research 2021; 2:38-79.
12. Blumenthal KG, Robinson LB, Camargo CA et al. Acute allergic reactions to mRNA COVID-19
vaccines. JAMA 2022; 325:1562-64.
13. Cadegiani FA. Catecholamines are the key trigger of mRNA SARS-CoV-2 and mRNA COVID-19
vaccine-induced myocarditis and sudden deahts: a compelling hypothesis supprted by
epidemiological, anatomopathological, molecular and physiological findings. medRxiv 2022.
14. Schauer J, Buddhe S, Gulhane A et al. Persistent cardiac MRI findings in a cohort of adolescents
with post COVID-19 mRNA vaccine myopericarditis. J Pediatr 2022.
15. Verma AK, Lavine KJ, Lin CY. Myocarditis after COVID-19 mRNA vaccination. N Engl J Med 2022;
385:1332-34.
16. Roltgen K, Nielsen SC, Silva O et al. Immune imprinting, breadth of variant recognition, and
germinal center response in human SARS-CoV-2 infection and vaccination. Cell 2022; 185:1-16.
17. Swank Z, Senussi Y, Alter G et al. Persistent circulating SARS-CoV-2 spike is associated with post-
acute COVID-19 sequelae. medRxiv 2022.
18. Patterson BK, Francisco EB, Yogendra R et al. Persistence of SARS CoV-2 S1 protein in CD16+
monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front
Immunol 2022; 12:746021.

19. Bortolotti D, Gentili V, Rizzo S et al. SARS-CoV-2 Spike 1 protein controls natural killer cell
activation via the HLA-E/NKG2A pathway. Cell 2020; 9:1975.
20. Gallardo-Zapata J, Maldonado-Bernal C. Natural killer cell exhaustion in SARS-CoV-2 infection.
Innate Immunity 2022; 28:1-10.
21. Lee MJ, Leong MW, Rustagi A et al. SARS-CoV-2 escapes direct NK cell killing through Nsp1-
mediated downreglaion of ligands NKG2D. bioRxiv 2022.
22. van Eeden C, Khqn L, Osman MS et al. Natural killer cell dysfunction and its role in COVID-19. Int
J Mol Sci 2020; 21:6351.
23. Gassen NC, Papies J, Bajaj T et al. Analysis of SARS-CoV-2 controlled autophagy reveals
spermidine, MK-2206 and niclosamide as putative antiviral therapeutics. bioRxiv 2020.
24. Verbeke R, Lentacker I, Smedt SC et al. Three decades of messenger RNA vaccine development.
Nanotoday 2019; 28:100766.
25. Parhiz H, Brenner JS, Patel PN et al. Added to pre-existing inflammation, mRNA-lipid
nanoparticles induce inflammation exacerbations (IE). Journal of Controlled Release 2022;
344:50-61.
26. Ndeupen S, Qin Z, Jacobsen S et al. The mRNA-LNP platform's lipid nanoparticle component
used in preclinical vaccine studies is highly inflammatory. iScience 2021; 24:103479.
27. Olajide O, Iwuanyanwu VU, Adegbola OD et al. SARS-CoV-2 spike glycoprotein S1 induces
neuroinflammation in BV-2 microglia. Molecular Neurobiology 2022; 59:45-458.
28. Nystrom S, Hammarstrom P. Amyloidogenesis of SARS-CoV-2 spike protein. Journal of the
American Chemical Society 2022.
29. Charnley M, Islam S, Bindra G et al. Neurotoxic amyloidogenic peptides identified in the
proteome of SARS-COV-2: potential implications for neurological symptoms in COVID-19. Nature
Communications 2022; 13:3387.
30. Mohabatkar H, Behbahani M, Moradi M. A concise in silico prediction report of a potential
prion-like doman in SARS-CoV-2 polyprotein. Journal of Microbiology, Biotechnology and Food
Sciences 2021; 11:e4813.
31. Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potenital
clues to neurodegeneration. Biochemical and Biophysical Research Communications 2021;
554:94-98.
32. Classen JB. Review of COVID-19 vaccines and the risk of chronic adverse events including
neurological degeneration. J Med Clin Res Rev 2021; 5:1-7.
33. Kuyandik A, Ozcan E, Serin S et al. Creutzfeldt-Jakob disease after COVID-19 vaccination. Turk J
Intensive Care 2021.
34. Perez JC, Moret-Chalmin C, Montagnier L. Towards the emergence of a new form of the
neurodegenerative Creutzfeldt-Jakob disease: Twenty six cases of CJD declared a few days after
a COVID-19 "vaccine" jab. Research Square 2022.
35. Clough E, Chean KT, Inigo J et al. Mitochondrial dynamics in SARS-CoV-2 spike protein treated
human microglia: Im plications for neuro-COVID. Journal of Neuroimmune Pharmacology 2022.
36. Schiaffino MT, Di Natale M, Garcia-Martinez E et al. Immunoserologic detection and diagnostic
relevance of cross-reactive autoantibodies in Coronavirus disease 2019 patients. J Infect Dis
2020; 222:1439-43.
37. Trahtemberg U, Fritzler MJ. COVID-19-associated autoimmunity as a feature of acute respiratory
failure. Intensive Care Med 2021.
38. Woodruff MC, Ramoneli RP, Lee FE et al. Broadly-targeted autoreactivity is common in severe
SARS-CoV-2 infection. medRxiv 2020.
39. Zuo Y, Estes SK, Ali RA et al. Prothrombotic autoantibodies in the serum from patients
hospitalized with COVID-19. Sci Translation Med 2020.

40. Pascolini S, Vannini A, Deleonardi G et al. COVID-19 and immunological dysregulation: can
autoantibodies be useful? Clin Trans Sci 2021; 14:502-8.
41. Wang EY, Mao T, Klein J et al. Diverse functional autoantibodies in patients with COVID-19.
Nature 2021; 595:283-88.
42. Nunez-Castilla J, Stebliankin V, Baral P et al. Potential autoimmunity resulting from molecular
mimicry between SARS-CoV-2 spike and human proteins. Viruses 2022; 14:1415.
43. Cabral-Marques O, Halpert G, Schimke LF et al. Autoantibodies targeting GPCRs and RAS-related
molecules associated with COVID-19 severity. Nature Communications 2022; 13:1220.
44. Arthur JM, Forrest JC, Boehme KW et al. Development of ACE2 autoantibodies after SARS-CoV-2
infection. PloS ONE 2021; 16:e0257016.
45. Wallukat G, Hohberger B, Wenzel K et al. Functional autoantibodies against G-protein coupled
receptors in patients with persistent Long-Covid-19 symptoms. Journal of Translational
Autoimmunity 2021; 4:100100.
46. Levine TD, Kafaie J, Zeidman LA et al. Cryptogenic small-fiber neuropathies: Serum autoantibody
binding to trisulfated heparin disaccharide and fibroblast growth factor receptor-3. Muscle &
Nerve 2020; 61:512-15.
47. Oaklander AL, Mills AJ, Kelley M et al. Peripheral neuropathy evaluations of patients with
prolonged long COVID. Neurol Neuroimmunol Neuroinflamm 2022; 9:e1146.
48. Burakgazi AZ. Small-fiber neuropathy possibly associated with COVID-19. Case Rep Neurol 2022;
14:208-12.
49. Shouman K, Vanichkachorn G, Chesire WP et al. Autonomic dysfunction following COVID-19
infection: an early experience. Clinical Autonomic Research 2021; 31:385-94.
50. Hinduja A, Moutairou A, Calvet JH. Sudomotor dysfunction in patients recovered from COVID-
19. Clinical Neurophysiology 2021; 51:193-96.
51. Abdelnour L, Abdalla ME, Babiker S. COVID 19 infection presenting as motor peripheral
neuropathy. Journal of the Formosan Medical Association 2020; 119:1119-20.
52. Abrams RM, Simpson DM, Navis A et al. Small fiber neuropathy associated with SARS-CoV-2
infection. Muscle & Nerve 2021.
53. Zhou L, Shin S. Small fiber neuropathy. Practical Neurology 2021;36.
54. Bednarik J, Bursova S, Dusek L et al. Etiology of small-fiber neuropathy. Journal of the Peripheral
Nervous System 2009; 14:177-83.
55. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation-
or should it be mast cell mediator disorders? Expert Rev Clin Immunol 2019; 15:639-56.
56. Weinstock LB, Brook JB, Walters AS et al. Mast cell activation symptoms are prevalent in Long-
COVID. International Journal of Infectious Diseases 2021; 112:217-26.
57. Gold JE, Okyay R, Licht WE et al. Investigation of Long COVID prevalence and its relationship to
Epstein-Barr Virus reactivation. Pathogens 2021; 10:763.
58. Chen T, Song J, Liu H et al. Positive Epstein-Barr virus detection in coronavirus disease 2019
(COVID-19) patients. Scientific Reports 2021; 11:10902.
59. Le Balc'h P, Pinceaux K, Pronier C et al. Herpes simplex virus and cytomegalovirus reactivations
among severe COVID-19 patients. Crit Care 2020; 24:530.
60. Peluso MJ, Deveau TM, Munter SE et al. Evidence of recent Epstein-Barr virus reactivation in
individuals experiencing Long Covid. medRxiv 2022.
61. Pont G, Pastorino L, Manfredini M et al. COVID-19 spreading across world correlates with C677T
allele of the methelenetetarhydrofolate reductase (MTHFR) geneprevalence. J Clin Lab Anal
2021; 35:e23798.

62. Karst M, Hollenhorst J, Achenbach J. Life-threatening course in coronavirus disease 2019
(COVID-19): Is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism
and hyperhomocysteinemia? Medical Hypotheses 2020; 114:110234.
63. Carpene G, Negrini D, Henry BM et al. Homocysteine in coronavirus disease (COVID-19): a
systematic literature review. Diagnosis 2022.
64. Ponti G, Roli L, Oliva G et al. Homocysteine (Hcy) assessment to predict outcomes of hospitalized
COVID-19 patients: a multicenter study on 313 Covid-19 patients. Clin Chem Lab Med 2021;
59:e354-e357.
65. Abu-Farha M, Al-Sabah S, Hammad MM et al. Prognostic genetic markers for thrombosis in
COVID-19 patients: A focused analysis on D-Dimer, homocysteine and thromboembolism.
Fronteirs in Pharmacology 2020; 11:587451.
66. Duma D, Collins JB, Chou JW et al. Sexually dimorphic actions of glucocorticoids provide a link to
inflammatory diseases with gender differences in prevalence. Science Signaling 2010; 3:ra74.
67. Atoui A, Jarrah K, Al Mahmassani L et al. Deep venous thrombosis and pulmonary embolism
after COVID-19 mRNA vaccination. Ann Hematol 2022; 101:1111-13.
68. Tomassetti F, Nuccetelli M, Sarubbi S et al. Evaluation of S-RBD and high specificity ACE-2
binding antibodies on SARS-CoV-2 patients after six months from infection. International
Immunopharmacology 2021; 99:108013.
69. Gundry SR. Observational findings of PULS cardiac test findings for inflammatory markers in
patients receiving mRNA vaccines. Circulation 2021; 144 (suppl. 1):A10712.
70. Decousus H, Tapson VF, Bergmann JF et al. Factors at admission associated with bleeding risk in
medical patients: findings from the IMPROVE investigators. Chest 2011; 139:69-79.
71. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk
of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;
138:1093-100.
72. Whitlock EP, Burda BU, Williams SB et al. Bleeding risks with aspirin use for primary prevention
in adults: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;
164:826-35.
73. Dans AL, Connolly SJ, Wallentin L et al. Concomitant use of antiplatelet therapy with dabigatran
or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Circulation 2013; 127:634-40.
74. Sumi H, Hamada H, Tsushima H et al. A novel fibrinolytic enzyme (nattokinase) in the vegetable
cheese Natto; a typical and popular food in Japanese diet. Experientia 1987; 43:1110-1111.
75. Weng Y, Yao J, Sparks S et al. Nattokinase: An oral antitrombotic agent for the prevention of
cardiovascular disease. Int J Mol Sci 2017; 18:523.
76. Dabbagh F, Negahdaripour M, Berenjian A et al. Nattokinase: production and application.
Applied Microbiology and Biotechnology 2014; 98:9199-206.
77. Nagata C, Wada K, Tamura T et al. Dietary soy and natto intake and cardiovascular disease
mortality in Japanese adults: the Takayama study. Am J Clin Nutr 2017; 105:426-631.
78. Sumi H, Hamada H, Nakanishi K et al. Enhancement of the fibrinolytic activity in plasma by oral
administration of nattokinase. Acta Haematol 1990; 84:139-43.
79. Hsia CH, Shen MC, Lin JS et al. Nattokinase decreases plasma levels of fibrinogen, factor VII, and
factor VIII in human subjects. Nutrition Research 2009; 29:190-196.
80. Kurosawa Y, Nirengi S, Homma T et al. A single-dose of oral nattokinase potentiates
thrombolysis and anti-coagulation profiles. Scientific Reports 2015; 5:11601.
81. Chen H, McGowan EM, Ren N et al. Nattokinase: A promising alternative in prevention and
treatment of cardiovascular diseases. Biomarker Insights 2018; 13:1-8.

82. Yatagai C, Maruyama M, Kawahara T et al. Nattokinase-promoted tissue plasminogen activator
release form human cells. Pathoyphysiol Haemost Thromb 2009; 36:227-32.
83. Jang JY, Kim TS, Cai J et al. Nattokinase improves blood flow by inhibiting platelet aggregation
and thrombus formation. Lab Anim Res 2013; 29:221-25.
84. Fujita M, Ohnishi K, Takaoka S et al. Antihypertensive effects of continuous oral administraion of
nattokinase and its fragment in spontaneously hypertensive rats. Biol Pharm Bull 2011; 34:1696-
701.
85. Tanikawa T, Kiba Y, Yu J et al. Degradative effect of Nattokinase on spike protein of SARS-CoV-2.
Molecules 2022; 27:5405.
86. Ren NN, Chen HJ, Li Y et al. A clinical study on the effect of nattokinase on carotid artery
atherosclerosis and hyperlipidemia [Chinese, Abstract in English]. Zhonghua Yi Vue Za Zhi 2017;
97:2038-42.
87. Chen H, Chen J, Zhang F et al. Effective management of atherosclerosis progress and
hyperlipidemia with nattokinase: A clinical study with 1,1062 participants. Front Cardiovasc Med
2022; 9:964977.
88. Fujita M, Hong K, Ito Y et al. Transport of nattokinase across the rat intestinal tract. Biol Pharm
Bull 1995; 18:1194-96.
89. Gallelli G, Di Mizio G, Palleria C et al. Data recorded in real life support the safety of Nattokinase
in patients with vascular diseases. Nutrients 2021; 13:2031.
90. Ramachandran L, Aqeel A, Jafri A et al. Nattokinase-associated hemoperitoneum in an elderly
woman. Cureus 2022; 13:-e20074.
91. Chnag YY, Liu JS, Lai SL et al. Cerebellar hemorrhage provoked by combinaed use of nattokinase
and aspirin in a patient with cerebral microbleeds. Inter Med 2008; 47:467-69.
92. Metkar SK, Girigoswami A, Vijayashree R et al. Attenuation of subcutaneous insulin induced
amyloid mass in vivo using lumbrokinase and serratiopeptidase. International Journal of
Biological Macromolecules 2020; 163:128-34.
93. Metkar SK, Girigoswami A, Murugesan R et al. Lumbrokinase for degradation and reduction of
amyloid fibriles associated with amyloidosis. Journal of Applied Biomedicine 2017; 15:96-104.
94. Metkar SK, Girigoswami A, Bondage DD et al. The potential of lumbrokinase and
serratiopeptidase for the degradation of AB 1-42 peptide - an invitro and insilico approach.
International Journal of Neuroscience 2022.
95. Chen Y, Liu Y, Zhang J et al. Efficacy and safety of lumbrokinase plus aspirin versus aspirin alone
for acute ischemic stroke (LUCENT): study protocl for a multicenter randomized controlled trial.
Trials 2022; 23:285.
96. Pretorius E, Venter C, Laubshder G et al. Combined triple treatment of fibrin amyloid microclots
and platelet pathology in individuals with long COVID/Post -acute sequelae of COVID-19 (PASC)
can resolve their persistent symptoms. Research Square 2021.
97. Gundry SR, Epstein J. Improvement in vascular reactivity by institution of a "green-Based" diet
with supplemental fish oil and polyphenolic compounds, grape seed extract and Pycnogenol.
Arteriosclerosis, Thrombosis and Vascular Biology 2012; 32:A310.
98. Fung J, Moore J. The complete guide to fasting. Victory Belt Publishing; 2016.
99. deCabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J
Med 2019; 381:2541-51.
100. Hannan A, Rahman A, Rahman S et al. Intermittent fasting, a possible priming tool for host
defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and
immune response. Immunology Letters 2020; 226:38-45.

101. Zhao Y, Jia M, Chen W et al. The neuroprotective effects of intermittent fasting on brain aging
and neurodegenerative diseases via regulating mitochondrial function. Free Radical Biology &
Medicine 2022; 182:206-18.
102. Beckman JA. Thrombolytic therapy for pulmonary embolism. JAMA 2014; 311:2385-86.
103. Cheng CW, Adams GB, Perin L et al. Prolonged fasting reduces IGF-1/PKA to promote
hematopoietic-stem-cell-based regeneration and reverse immunosppression. Cell Stem Cell
2014; 14:810-823.
104. Hine C, Mitchell JR. Saying No to drugs: Fasting protects hematopoietic stem cells from
chemotherapy and aging. Cell Stem Cell 2014; 14:704.
105. Lustig RH. Metabolical. The lure and lies of processed food, Nutrition and Modern Medicine.
Harper; 2021.
106. Pietrocola F, Malik SA, Marino G et al. Coffee induces autophagy in vivo. Cell Cycle 2014;
13:1987-94.
107. Ray K. Caffeine is a potent stimulator of autophagy to reduce hepatic lipid content - a coffee for
NAFLD? Nature Reviews Gastroenterology & Hepatology 2013; 10:563.
108. Sinha RA, Farah BL, Singh BK et al. Caffeine stimulates hepatic lipid metabolism by the
autophagy-lysosomal pathway in mice. Hepatology 2014; 59:1366-80.
109. Dacasin AB, Diagono DM, So PK et al. The potential use of virgin coconut oil as an adjunctive
treatment for COVID-19: A review. Journal of Pharmacognosy and Phytochemistry 2021; 10:37-
49.
110. Teng M, Zhao YJ, Khoo AL et al. Impact of coconut oil consumption on cardiovascular health: a
systematic review and meta-analysis. Nutr Rev 2019; 78:249-59.
111. Santos HO, Howell S, Earnest CP et al. Coconut oil intake and its effects on the cardiometabolic
profile - A structured literature review. Progress in Cardiovascular Diseases 2019; 62:436-43.
112. Mostafa DK, Khedr MM, Barakat MK et al. Autophagy blockade mechanistically links proton
pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of
metformin/enalapril. Life Sci 2021; 265:118818.
113. Panahi Y, Khedmat H, Valizadegan G et al. Efficacy and safety of Aloe vera syrup for the
treatment of gastro-esophageal reflux disease: a pilot randomized positive-controlled trial. J
Tradit Chin Med 2015; 35:632-36.
114. Brown R, Sam CH, Green T et al. Effect of GutsyGum, a Novel Gum, on subjective ratings of
gastro esophageal reflux following a refluxogenic meal. Journal of Dietary Supplements 2015;
12:138-45.
115. Liu J, Liang H, Chen C et al. Ivermectin induces autophagy-mediated cell death through
AKT/mTOR signaling pathway in glioma cells. Bioscience Reports 2019; 39:BSR20192489.
116. Tripathy S, Dassarma B, Roy S et al. A review on possible modes of
chloroquine/hydroxychloroquine: repurposing against SARS-CoV-2 (COVID-19) pandemic.
International Journal of Antimicrobial Agents 2020; 56:106028.
117. Morishita H, Mizushima N. Diverse cellular roles of autophagy. Annu Rev Cell Dev Biol 2019;
35:3.1-3.23.
118. Xu R, Ji Z, Xu C et al. The clinical value of using chloroquine or hydroxychloroquine as autophagy
inhibitors in the treatment of cancers. A systematic review and meta-analysis. Medicine 2018;
97:46.
119. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for
glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med
2006; 144:337-43.

120. Wolpin BM, Rubinson DA, Wang X et al. Phase II and pharmacodynamic study of autophagy
inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. The
Oncologist 2014; 19:637-38.
121. Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: Recent advances and
future directions. Cancer Discov 2019; 9:1167-81.
122. Zeh HJ, Bahary N, Boone BA et al. A randomized Phase II preoperative study of autophagy
inhibition with high-dose hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in pancreatic
cancer patients. Clinical Cancer Research 2020; 26:3126-34.
123. de Groot S, Lugtenberg RT, Cohen D et al. Fasting mimicking diet as an adjunct to neoadjuvent
chemotherapy for breast cancer in multicentre randomized phase 2 DIRECT trial. Nature
Communications 2020; 11:3083.
124. Lugtenberg RT, de Groot S, Kaptein AA et al. Quality of life and illness perceptions in patients
with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in
the phase 2 DIRECT (BOOG 2013-14) trial. Breast Cancer Research and Treatment 2022;
185:741-58.
125. Nencioni A, Caffa I, Cortellino S et al. Fasting and cancer: molecular mechanisms and clinical
application. Nat Rev Cancer 2018; 18:707-19.
126. Martin B, Pearson M, Kebejian L et al. Sex-dependent metabolic, neuroendocrine, and cognitive
responses to dietary energy restriction and excess. Endocrinology 2007; 148:4318-33.
127. Kumar S, Kaur G. Intermittent fasting dietary restriction regimen negatively influences
reproduction in young rats: A study of hypothalamo-hypophysial-gonadal axis. PloS ONE 2013;
8:e52416.
128. Cienfuegos S, Corapi S, Gabel K et al. Effects of intermittent fasting on reproductive hormone
levels in females and males: A review of human trials. Nutrients 2022; 14:2343.
129. Heilbronn LK, Civitarese AE, Bogacka I et al. Glucose tolerance and skeletal muscle gene
expression in response to alternate day fasting. Obesity Research 2005; 13:574-81.
130. Li C, Xing C, Zhang J et al. Eight-hour time restricted feeding improves endocrine and metabolic
profiles in women with anovulatory polycystic ovary syndrome. J Transl Med 2021; 19:148.
131. Jakubowicz D, Barnea M, Wainstein J et al. Effects of caloric intake timing on insulin resistance
and hyperandrogenism in lean women with polycystic ovary syndrome. Clinical Science 2013;
125:423-32.
132. Saha JK, Raihan J. The binding mechanism of ivermectin and levosalbutamol with spike protein
of SARS-CoV-2. Research Square 2021.
133. Bello M. Elucidation of the inhibitory activity of ivermectin with host nuclear importin alpha and
several SARS-CoV-2 targets. Journal of Biomolecular Structure and Dynamics 2021.
134. Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain
attached to ACE2. In Vivo 2020; 34:3023-26.
135. Ci X, Li H, Yu Q et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear
transcription factor kappa-B and mitogen activated protein kinase pathway. Fundamental &
Clinical Pharmacology 2009; 23:449-55.
136. DiNicolantonio JJ, Barroso-Arranda J, McCarty M. Ivermectin may be a clinically useful anti-
inflammatory agent for late-stage COVID-19. Open Heart 2020; 7:e001350.
137. Yan S, Ci X, Chen N et al. Anti-inflammatory effects of ivermectin in mouse model of allergic
asthma. Inflamm Res 2011; 60:589-96.
138. Nicolas P, Maia MF, Bassat Q et al. Safety of oral ivermectin during pregnancy: a systematic
review and meta-analysis. Lancet Glob Health 2020; 8:e92-e100.

139. Poenaru S, Abdallah SJ, Corrales-Medina V et al. COVID-19 and post-infectious myalgic
encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infectious Dis 2021;
8:1-16.
140. Raman B, Cassar MP, Tunnicliffe EM et al. Medium-term effects of SARS-CoV-2 infection on
multiple vital organs, exercise capacity, cognition, quality of life and mental health, post hospital
discharge. EClinicalMedicine 2022; 31:100683.
141. Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of
Myalgic Encephalolyelitis/Chronic Fatigue Syndrome (ME/CFS_. Int J Clin Exp Med 2012; 5:208-
20.
142. Wood E, Hall KH, Tate W. Role of mitochondria, oxidative stress and the response to
antioxidants in myalgic enecphalomyelitis/Chronic fatigue syndrome: A possible approach to
SARS-CoV-2 'long-haulers'? Chronic Diseases and Translational Medicine 2021; 7:14-26.
143. Brown JT, Saigal A, Karia N et al. Ongoing exercise intolerance following COVID-19: A magnetic
resonance-Augmented Cardiopulmonary excercise Test Study. J Am Heart Assoc 2022;
11:e024207.
144. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-
inflammatory treatment for chronic pain. Clin Rheumatol 2014; 33:451-59.
145. Toljan K, Vrooman B. Low-dose naltrexone (LDN) - Review of therapeutic utilization. Med Sci
2018; 6:82.
146. Molina-Carballo A, Palacios-Lopez R, Jerez-Calero A et al. Protective effect of melatonin
administration against SARS-CoV-2 infection: A systematic review. Current Issues in Molecular
Biology 2022; 44:31-45.
147. Hasan ZT, AlAtrakji MQ, Mehuaiden AK. The effect of melatonin on thrombosis, sepsis and
mortality rate in COVID-19 patients. International Journal of Infectious Diseases 2022; 114:79-
84.
148. Reiter RJ, Sharma R, Ma Q et al. Plasticity of glucose metabolism in activated immune cells:
advantages for melatonin inhibition of COVID-19 disease. Melatonin Res 2020; 3:362-79.
149. Reiter RR, Sharma R, Castillo R et al. Coronavirus-19,Monocyte/Macrophage glycolysis and
inhibition by melatonin. J SARS-CoV2 COVID 2021; 2:29-31.
150. Colunga Biancatelli RM, Berrill M, Mohammed YH et al. Melatonin for the treatment of sepsis:
the scientific rationale. J Thorac Dis 2020; 12 (Suppl 1):S54-S65.
151. Rylander R. Bioavailability of magnesium salts - A review. Journal of Pharmacy and Nutrition
Sciences 2014; 4:57-59.
152. Uysal N, Kizildag S, Yuce Z et al. Timeline (Bioavailability) of magnesium compounds in hours:
Which magnesium compound works best? Biological Trace Element Research 2018.
153. Li W, Yu J, Liu Y et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive
deficits in Alzheimer's disease mouse model. Molecular Brain 2014; 7:65.
154. Di Y, He YL, Zhao T et al. Methylene blue reduces acute cerebral ischemic injury via the induction
of mitophagy. Mol Med 2015; 21:420-429.
155. Jiang Z, Watts LT, Huang S et al. The effects of methylene blue on autophagy and apoptosis in
MRI-defined normal tissue, ischemic penumbra and ischemic core. PloS ONE 2015;
10:e0131929.
156. XIe L, Li W, Winters A et al. Methylene blue induces macroautophagy through 5' adenosine
monophosphate-activated protein kinase pathway to protect neurons from serum deprivation.
Fronteirs in Cellular Neuroscience 2013; 7:56.
157. Peter C, Hongwan D, Kupfer A et al. Pharmacokinetics and organ distribution of intravenous and
oral methylene blue. Eur J Clin Pharmacol 2000; 56:247-50.

158. Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection - An emerging role for
methylene blue. Mol Neurobiol 2018; 55:5137-53.
159. Yang L, Youngblood H, Wu C et al. Mitochondria as a targer for neuroprotection: role of
methylene blue and photobiomodulation. Translational Neurodegeneration 2020; 9:19.
160. Gonzalez-Lima F, Auchter A. Protection against neurodegeneration with low-dose methylene
blue and near-infrared light. Fronteirs in Cellular Neuroscience 2015; 9:179.
161. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement
and neuroprotection of methylene blue. Prog Neurobiol 2012; 96:32-45.
162. Heiskanen V, Pfiffner M, Partonen T. Sunlight and health; shifting the focus from vitamin D3 to
photobiomodulation by red and near-infrared light. Ageing Research Reviews 2022; 61:101089.
163. Whitten A. The Ultimate guide to red light therapy. Archangel Ink; 2018.
164. Hobday RA, Cason JW. The open-air treatment of pandemic influenza. Am J Public Health 2022;
99 Suppl.2:S236-S242.
165. Lindqvist PG, Epstein E, Landin-Olsson M et al. Avoidance of sun exposure is a risk factor for all-
cause mortality: results form the Melanoma in Southern Sweden cohort. Journal of Internal
Medicine 2014; 276:77-86.
166. Hamblin MR. Mechanisms and application of the anti-inflammatory effects of
photobiomodulation. AIMS Biophys 2017; 4:337-61.
167. Yeager RL, Oleske DA, Sanders RA et al. Melatonin as a principal component of red light therapy.
Medical Hypotheses 2007; 69:372-76.
168. Aguida B, Pooam M, Ahmad M et al. Infrared light therapy relieves TLR-4 dependent hyper-
inflammation of the type induced by COVID-19. Communicative & Integrative Biology 2021; 14:-
200.
169. Hamblin MR. Shining light on the head: Photobiomodulation for brain disorders. BBA Clinical
2016; 6:113-24.
170. Hamblin MR. Photobiomodulation for Alzheimer's disease: Has the light dawned? Photonics
2019; 6:77.
171. Cassano P, Petrie SR, Cusin C et al. Transcranial photobiomodulation for the treatment of major
depressive disorder. The ELATED-2 pilot trial. Photomedicine and Laser Surgery 2018; 36:634-46.
172. Nizamutdinov D, Qi X, Berman MH et al. Transcranial near infrared light stimulations improve
cognition in patients with dementia. Aging and Disease 2021; 12.
173. Liebert A, Bicknell B, Markman W et al. A potential role for photobiomodulation therapy in
disease treatment and prevention in the era of COVID-19. Aging and Disease 2020; 11:1352-62.
174. Pereira PC, de Lima CJ, Fernandes AB et al. Cardiopulmonary and hematological effects of
infrared LED photobiomodulation in the treatment of SARS-COV2. Journal of Phtotochemistry &
Photobiology, B: Biology 2023; 238:112619.
175. Gligorijevic N, Stanic-Vucinic D, Radomirovic M et al. Role of resveratrol in prevention and
control of cardiovascular disorders and cardiovascular complications related to COVID-19
disease: Mode of action and approaches explored to increase its bioavailability. Molecules 2021;
26:2834.
176. Pandey P, Rane JS, Chatterjee A et al. Targeting SARS-CoV-2 spike protein of COVID-19 with
naturally occuring phytochemicals: an in silico study for drug development. Journal of
Biomolecular Structure and Dynamics 2020.
177. de Sa Coutinho D, Pacheco MT, Frozza RL et al. Anti-inflammatory effects of resveratrol:
Mechanistic insights. International Journal of Molecular Sciences 2018; 19:1812.
178. Park D, Jeong H, Lee MN et al. Resveratrol induces autophagy by directly inhibiting mTOR
through ATP competition. Scientific Reports 2016; 6:21772.

179. Kou X, Chen N. Resveratrol and natural autophagy regulator for prevention and treatment of
Alzheimers disease. Nutrients 2017; 9:927.
180. De Santi C, Pietrabissa A, Spisni R et al. Sulphation of resveratrol, a natural compound present in
wine, and its inhibition by natural flavonoids. Xenobiotica 2000; 30:857-66.
181. Yang JY, Della-Fera MA, Rayalam S et al. Enhanced inhibition of adipogenesis and induction of
apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci 2008;
82:1032-39.
182. Saeedi-Boroujeni A, Mahmoudian-Sani MR. Anti-inflammatory potential of Quercetin in COVID-
19 treatment. J Inflamm 2021; 18:3.
183. Chan EW, Wong CW, Tan YH et al. Resveratrol and pterostilbene: A comparative overview of
their chemistry, biosynthesis, plant sources and pharmacological properties. Journal of Applied
Pharmaceutical Science 2019; 9:124-29.
184. Chang J, Rimando A, Pallas M et al. Low-dose pterostilbene, but not resveratrol, is a potent
neuromodulator in aging and Alzheimers's disease. Neurobiology of Aging 2012; 33:2062-71.
185. Liu Y, You Y, Lu J et al. Recent advances in synthesis, bioactivity, and pharmacokinetics of
Pterostilbene an important analog of resveratrol. Molecules 2020; 25:5166.
186. Walle T. Bioavailability of resveratrol. Ann New York Acad Sci 2011; 1215:9-15.
187. Sathyapalan T, Manuchehri AM, Thatcher NJ et al. The effect of soy phytoestrogen
supplementation on thyroid status and cardiovascular risk markers in patients with subclinical
hypothyroidism: A randomized, double-blind, crossover study. J Clin Endocrinol Metab 2020;
96:1422-49.
188. Gutierrez-Castrellon P, Gandara-Marti T, Abreu AT et al. Probiotic improves symptomatic and
viral clearance in Covid-19 outpatients: a randomized, quadruple-blinded, placebo-conttrolled
trial. GUT Microbes 2022; 14:e2018899.
189. Zuo T, Wu X, Wen W et al. Gut microbiome alterations in COVID-19. Genomics, Proteomics &
Bioinformatics 2021.
190. Chen Y, Gu S, Chen Y et al. Six-month follow-up of gut microbiota richness in patients with
COVID-19. Gut 2021.
191. Thomas R, Aldous J, Forsyth R et al. The inflence of a blend of probiotic Lactobacillus and
prebiotic inulin on the duration and severity of symptoms among individuals with COVID-19.
Infect Dis Diag Treat 2022; 5:12.
192. Izquierdo JL, Soriano JB, Gonzalez Y et al. Use of N-Acetylcysteine at high doses as an oral
treatment for patients with COVID-19. Science Progress 2022; 105.
193. Shi Z, Puyo CA. N-Acetylcysteine to combat COVID-19: an evidence review. Therapeutics and
Clinical Risk Management 2020; 16:1047-55.
194. De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both
prevention and adjuvant therapy of COVID-19. FASEB J 2020.
195. Schmitt B, Vicenzi M, Garrel C et al. Effects of N-acetylcysteine, oral glutathione (GSH) and a
novel sublingual for of GSH on oxidative stress markers: A comparative crossover study. Redox
Biology 2015; 6:198-205.
196. Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress
biomarkers in human volunteers. Journal of Alternative & Complementary Medicine 2011;
17:827-33.
197. Sinha R, Sinha I, Calcagnotto A et al. Oral supplementation with liposomal glutathione elevates
body stores of glutathione and markers of immune function. Eur J Clin Nutr 2018; 72:105-11.
198. Yoon JK, Frankel AE, Feun LG et al. Arginine deprivation therapy for malignant melanoma.
Clinical Pharmacology Advances and Applications 2013; 5:11-19.

199. Stang A, Robers J, Schonert B et al. The performance of the SARS-CoV-2 RT-PCR test as a tool for
detecting SARS-CoV-2 infection in the population. J Infect 2021; 83:244-45.
200. Lee CR, Zeldin DC. Resolvin infectious inflammation by targeting the host response. N Engl J Med
2015; 373:2183-85.
201. Serhan CN. Novel pro-resolving lipid mediators in inflammation are leads for resolution
physiology. Nature 2014; 510:92-101.
202. Kosmopoulos A, Bhatt L, Meglis G et al. A randomized trial of Icosapent Ethyl in ambulatory
patients with COVID-19. iScience 2021; 24:103040.
203. Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary
events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint
analysis. Lancet 2007; 369:1090-1098.
204. Harris WS. Understanding why REDUCE-It was positive-mechanistic overview of
eicosapentaenoic acid. Progress in Cardiovascular Diseases 2019; 62:401-5.
205. Bhatt D, Steg PG, Miller M et al. Cardiovascular risk reduction with icosapent ethyl for
hypertriglyceridemia. N Engl J Med 2019; 380:-11.
206. Kastelstein JJ, Stroes ES. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med 2019;
380:89-91.
207. Guo XF, Li KL, Li JM et al. Effects of EPA and DHA on blood pressure and inflammatory factors: a
meta-analysis of randomized controlled trials. Clinical Reviews in Food Science and Nutrition
2019; 59:3380-3393.
208. von Schacky C. Importance of EPA and DHA blood levels in brain structure and funcion.
Nutrients 2021; 13:1074.
209. Cottin SC, Sanders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk
factors. Proceeding of the Nutrition Society 2011; 70:215-31.
210. Allaire J, Couture P, Leclerc M et al. A randomized, crossover, head to head comparison of
eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation
markers in men and women: the Comparing PA to DHA (ComparED) study. Am J Clin Nutr 2016;
104:280-287.
211. Santamarina MG, Boisier D, Contreras R et al. COVID-19: a hypothesis regarding the ventilation-
perfusion mismatch. Crit Care 2020; 24:395.
212. Mario L, Roberto M, Marta L et al. Hypothesis of COVID-19 therapy with sildenafil. International
Journal of Preventive Medicine 2020; 11:76.
213. Santamarina MG, Beddings I, Martinez Lomakin F et al. Sildenafil for treating patients with
COVID-19 and perfusion mismatch: a pilot randomized trial. Crit Care 2022; 26:1.
214. Kniotek M, Boguska A. Sildenafil can affect innate and adaptive immune system in both
experimental animals and patients. Journal of Immunology Research 2017; 2017:4541958.
215. Isidori AM, Giannetta E, Pofi R et al. Targeting the NO-cGMP-PDE5 pathoway in COVID-19
infection. The DEDALO project. Andrology 2021; 9:33-38.
216. Al-kuraishy HM, Ali-Gareeb AI, Al-Niemi MS et al. COVID-19 and phosphodiesterase enzyme type
5 inhibitors. J Microsc Ultrastruct 2022; 8:141-45.
217. Islam MT, Guha B, Hosen S et al. Nigellalogy: A review on Nigella Sativa. MOJ Bioequiv Availab
2017; 3:00056.
218. Ashraf S, Ashraf S, Ashraf M et al. Honey and Nigella sativa against COVID-19 in Pakistan (HNS-
COVID-PK): A multi-center placebo-controlled randomized clinical trial. medRxiv 2021.
219. Barbash IJ, Davis BS, Yabes JG et al. Treatment patterns and clinical outcomes after the
introduction of the Medicare Sepsis Performance Measure (SEP-1). Ann Intern Med 2021.

220. Fakhar-e-Alam Kulyar M, Li R, Mehmood K et al. Potential influence of Nagella sativa (Black
cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic.
Phytomedicine 2021; 85:153277.
221. Hannan MA. Black Cumin (Nigella sativa L.): A Comprehensive Review on Phytochemistry, Health
Benefits, Molecular Pharmacology, and Safety. Nutrients 2021; 13.
222. Warner ME, Naranjo J, Pollard EM et al. Serotonergic medications, herbal supplements, and
perioperative serotonin syndrome. Can J Anaesth 2017; 64:940-946.
223. Marik PE. Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) for the treatment of sepsis.
Focus on ascorbic acid. Nutrients 2018; 10:1762.
224. Marik PE. Vitamin C for the treatment of sepsis: The scientific rationale. Pharmacol Therapeut
2018; 189:63-70.
225. Colunga Biancatelli RM, Berrill M, Marik PE. The antiviral properties of vitamin C. Expert Rev Anti
Infect Ther 2020; 18:99-101.
226. Miranda-Massari JR, Toro AP, Loh D et al. The effects of vitamin C on the multiple pathological
stages of COVID-19. Life 2021; 11:1341.
227. Holford P, Carr AC, Zawari M et al. Vitamin C intervention for Critical COVID-19: A pragmatic
review of the current level of evidence. Life 2021; 11:1166.
228. Madeo F, Eisenberg T, Pietrocola F et al. Spermidine in health and disease. Science 2018;
359:410.
229. Eisenberg T, Abdellatif M, Schroeder S et al. Cardioprotection and lifespan extension by natural
polyamine spermidine. Nat Med 2016; 22:1428-38.
230. Morselli E, Marino G, Bennetzen MV et al. Spermidine and resveratrol induce autophagy by
distinct pathways converging on the acetylproteome. J Cell Biol 2022; 192:615-29.
231. Kiechl S, Pechlaner R, Willeit P et al. Higher spermidine intake is linked to lower mortality: a
prospective population-based study. Am J Clin Nutr 2018; 108:371-80.
232. Nowotarski SL, Woster PM, Casero RA. Polyamines and cancer: implications for
chemoprevention and chemotherapy. Expert Rev Mol Med 2014.
233. Zheng L, Xie Y, Sun Z et al. Serum spermidine in relation to risk of stroke: A multilevel study.
Front Nutr 2022; 9:843616.
234. Sabel BA, Flammer J, Merabet LB. Residual vision activation and the brain-eye-vascular triad:
Dysregulation, plasticity and restoration in low vision and blindness - a review. Restorative
Neurology and Neuroscience 2018; 36:767-91.
235. Siegert A, Diedrich L, Antal A. New methods, old brains - A systematic review on the effects of
tDCS on cognition of elderly people. Fronteirs in Human Neuroscience 2021; 15:730134.
236. Teselink J, Bawa KK, Koo GK et al. Efficacy of non-invasive brain stimulation on global cognition
and neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairement: A meta-
analysis and systematic review. Ageing Research Reviews 2021; 72:101499.
237. Sabel BA, Zhou W, Huber F et al. Non-invasive brain microcurrent stimulation therapy of long-
COVID-19 reduces vascular dysregulation and improves visial and cognitive impairement.
Restorative Neurology and Neuroscience 2021; 39:393-408.
238. Ahorsu DK, Adjaottor ES, Lam BY. Intervention effect of non-invasive brain stimulation on
cognitive functions among people with traumatic brain injury: A systematic review and meta-
analysis. Brain Sci 2021; 11:840.
239. Finisguerra A, Borgatti R, Urgesi C. Non-invasive brain stimulation for the rehabilitation of
children and adolescents with neurodevelopmental disorders: A systematic review. Fronteirs in
Psychology 2019; 10:135.

240. Chen JJ, Zeng BS, Wu CN et al. Association of central noninvasive brain stimulation interventions
with efficacy and safety in tinnitus management. A meta-analysis. JAMA Otolaryngol Head Neck
Surg 2020; 146:801-9.
241. Chen JJ, Zeng BY, Lui CC et al. Pfizer-BioNTech COVID-19 vaccine-associated tinnitus and
treatment with transcranial magnetic stimulation. QJM 2022.
242. Sanabria-Mazo JP, Montero-Marin J, Feliu-Soler A et al. Mindfulness-based program plus
amygdala and inusla retraining (MAIR) for the treatment of women with fibromyalgia: A pilot
ramdomized controlled trial. J Clin Med 2020; 9:3246.
243. Yong SJ. Long-haul COVID-19: Putative pathophysiology, risk factors, and treatments. medRxiv
2020.
244. Shu C, Feng S, Cui Q et al. Impact of Tai Chi on CRP, TNF-alpha and IL-6 in inflammation: a
systematic review and meta-analysis. Ann Palliat Med 2021; 10:7468-6478.
245. Zhang Z, Ren JG, Guo JL et al. Effects of Tai Chi and Qigong on rehabilitation after COVID-19: a
protocl for systematic review and meta-analysis. BMJ Open 2022; 12:e059067.
246. Falkenberg RI, Eising C, Peters ML. Yoga and immune system functioning: a systematic review of
randomized controlled trials. J Behav Med 2018; 41:467-82.
247. Robbins T, Gonevski M, Clark C et al. Hyperbaric oxygen therapy for the treatment of long
COVID: early evaluation of a highly promising intervention. Clinical Medicine 2021; 21:e629-
e632.
248. Oliaei S, Mehrtak M, Karimi A et al. The effects of hyperbaric oxygen therapy (HBOT) on
coronavirus disease-2019 (COVID-19): a systematic review. Eur J Med Res 2021; 26:96.
249. Senniappan K, Jeyabalan S, Rangappa P et al. Hyperbaric oxygen therapy: Can it be a novel
supportive therap in COVID-19? Indian Journal of Anaesthesia 2020; 64:835-41.
250. Kjellberg A, De Maio A, Lindholm P. Can hyperbaric oxygen safely serve as an inti-inflammatory
treatment for COVID-19? Medical Hypotheses 2020; 144:110224.
251. Hadanny A, Abbott S, Suzin G et al. Effect of hyperbaric oxygen therapy on chronic
neurocognitive deficits of post-traumatic brain injury patients: retrospective analysis. BMJ Open
2018; 8:e023387.
252. Han CH, Zhang PX, Xu WG et al. Polarization of macrophages in the blood after decompression in
mice. 7 2017;240.
253. De Maio A, Hightower LE. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric
oxygen therapy (HBOT): what is the link? Cell Stress & Chaperones 2020; 25:717-20.
254. Buras JA, Holt D, Orlow D et al. Hyperbaric oxygen protects from sepsis mortality via an
interleukin-10-dependent mechanism. Crit Care Med 2006; 34:2624-29.
255. Tezgin D, Giardina C, Perdrizet GA et al. The effect of hyperbaric oxygen on mitochondrial and
glycolytic energy metabolism: the caloristasis concept. Cell Stress and Chaperones 2020; 25:667-
77.
256. Zilberman-Itskovich S, Catalogna M, Sasson E et al. Hyperbaric oxygen therapy improves
neurocognitive functions and sumptoms of post-COVID condition: randomized controlled trial.
Scientific Reports 2022; 12:11252.
257. Mogil RJ, Kaste SC, Ferry RJ et al. Effect of low-magnitude, high-frequency mechanical
stimulation on BMD among young childhood cancer survivors. A randomized clinical trial. JAMA
Oncol 2016; 2:908-15.
258. Misra HS, rajpurohit YS, Khairnar NP. Pyrroloquinoline-quinone and its versatile roles in
biological processes. J Biosci 2012; 37:312-25.
259. Akagawa M, Nakano M, Ikemoto K. Recent progress in studies on the health benefits of
pyrroloquinoline quinone. Bioscience, Biotenchnology, and Biochemistry 2016; 80:13-22.

260. Hamilton D, Jensen GS. Nutraceutical support of mitochondrial function associated with
reduction of long-term fatigue and inflammation. Alternative Therapies in Health & Medicine
2021; 27:8-18.
261. Nicolson GL, Settineri R, Ellithorpe R. Lipid replacement therapy with a glycopholipid
formulation of NADH and CoQ10 significantl reduces fatigue in intractable chronic fatiguing
illnesses and chronic lyme disease patients. International Journal of Clinical Medicine 2012;
3:163-70.
262. Chowanadisiai W, Bauerly KA, Tchaparian E et al. Pyrroloquinoline quinone stimulates
mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and
increased PGC-1alpha expression. J Biol Chem 2010; 285:142-52.
263. Nicolson GL, Settineri R. Lipid replacement therapy: a functional food approach with new
formulations for reducing cellular oxidative damage, cancer-associated fatigue and the adverse
effects of cancer therapy. Functional Foods in Health and Disease 2011; 1:135-60.
264. Nicolson GL, Rosenblatt S, de Mattos GF et al. Clinical uses of membrane lipid replacement
supplements in restoring membrane function and reducing fatigue in chronic disease and
cancer. Discoveries 2016; 4:e54.
265. Shukla AM, Shukla AW. Expanding horizons for clinical applications of chloroquine,
hydroxychloroquine and related structural analogues. Drugs in Context 2019; 8:2019-9-1.
266. Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in
infectious, immune, neoplastic and neurological diseases: A mini review. Clin Drug Invest 2018;
38:653-71.
267. Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus
2008; 17:271-73.
268. de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and
recurrent miscarriage. Br J Clin Pharmac 2020; 86:39-49.
269. Siso A, Ramos-Casals M, Bove A et al. Previous antimalarial therapy in patients diagnosed with
lupus nephritis: Influence on outcomes and survival. Lupus 2008; 17:281-88.
270. Servy EJ, Jacquesson-Fournols L, Cohen M et al. MTHFR isoforms carriers. 5-MTHF (5-methyl
tetrahydrofolate) vs folic acid: a key to pregnancy outcome: a case series. Journal of Assisted
Reproduction and Genetics 2018; 35:1431-35.
271. Jamme M, Mazeraud A. Plasmapheresis efficiency in Coronavirus disease 2019: More related to
what you add and not what you take away? Crit Care Med 2021.
272. Patidar GK, Land KJ, Vrielink H et al. Understanding the role of therapeutic plasma exchange in
COVID-19: preliminary guidance and practices. Vox Sanguinis 2021.
273. Hashemian SM, Shafigh N, Afzal G et al. Plasmapheresis reduces cytokine and immune cell levels
in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonary 2021; 27:486-
92.
274. Balagholi S, Dabbaghi R, Eshghi P et al. Potential of therapeutic plasmapharesis in treatment of
COVID-19 patients: immunopathogenesis and coagulopathy. Transfusion and Apheresis Science
2020; 59:102993.
275. Keith P, Day M, Perkins L et al. A novel treatment approach to the novel coronavirus: an
argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care 2020;
24:128.
276. Morath C, Weigand MA, Zeier M et al. Plasma exchange in critically ill COVID-19 patients. Crit
Care 2020; 24:481.
277. Fernandez J, Gratacos-Gines J, Olivas P et al. Plasma exchange: An effective rescue therapy in
critically ill patients with Coronavirus Disease 2019 infection. Crit Care Med 2020.

278. Gucyetmez B, Atalan HK, Sertdemir I et al. Therapeutic plasma exchange in patients with COVID-
19 pneumonia in intensive care unit: a retrospective study. Crit Care 2020; 24:492.
279. Kiprov DD, Herskowitz A, Kim D et al. Case report. Therapeutic and immunomodulatory effects
of plasmapheresis in long-haul COVID. F1000Research 2022; 10:1189.
280. Pitt B, Sutton NR, Wang Z et al. Potential repurposing of the HDAC inhibitor valproic acid for
patients with COVID-19. Eur J Pharmacol 2021; 898:173988.
281. Unal G, Turan B, Balcioglu YH. Immunopharmacological management of COVID-19: Potential
therapeutic role of valproic acid. Medical Hypotheses 2020; 14:109891.
282. Wu C, Li A, Leng Y et al. Histone deacetylase inhibition by sodium valproate regulates
polarization of macrophage subsets. DNA and Cell Biology 2012; 31:592-99.
283. Larsson P, Alwis I, Niego B et al. Valproic acid selectively increases vascular endothelial tissue -
type plasminogen activator production and reduces thrombus formation in the mouse. J Thromb
Haemost 2016; 14:2496-508.
284. Koriyama Y, Sugitani K, Ogai K et al. Heat shock protein 70 induction by valproic acid delays
photoreceptor cell death ny N-methyl-N-nitrosurea in mice. J Neurochem 2014; 130:707-19.
285. Fleisher AS, Truran D, Mai JT et al. Chronic divalproex sodium use and brain atrophy in
Alzheimers disease. Neurology 2011; 77:1263-71.
286. Faggi L, Pignataro G, Parrella E et al. Synergistic association of valproate and resveratrol reduces
brain injury in ischemic stroke. Int J Mol Sci 2018; 19:172.
287. Chen Y, Lin PX, Hsieh GL et al. The proteomic and genomic teratogenicity elicited by valproic acid
is preventable with resveratrol and alpha-tocopherol. PloS ONE 2014; 9:e116534.
288. Santos-terra J, Deckmann I, Carello-Collar G et al. Resveratrol prevents cytoarchitectural and
interneuronal alterations in the valproic acid model of autism. Int J Mol Sci 2022; 23:4075.
289. Cohen M. Turning up the heat on COVID-19: heat as a therapeutic intervention. F1000Research
2020; 9:292.
290. Ramirez FE, Sanchez A, Pirskanen AT. Hydrothermotherapy in prevention and treatment of mild
to moderate cases of COVID-19. Medical Hypotheses 2021; 146:110363.
291. Hussain J, Cohen M. Clinical effects of regular dry sauna bathing: A systematic review. Evidence-
Based Complementary and Alternative Medicine 2018; 2018:1857413.
292. Laukkanen JA, Laukkanen T, Kunustor SK. Cardiovascular and other health benefits of sauna
bathing: A review of the evidence. Mayo Clin Proc 2018; 93:1111-21.
293. Laukkanen T, Khan H, Zaccardi F et al. Association between sauna bathing and fatal
cardiovascular and all-cuase mortality. JAMA Intern Med 2015; 175:542-48.
294. Janssen CW, Lowry CA, Mehl MR et al. Whole-body hyperthermia for the treatment of major
depressive disorder.A randomized Clinical Trial. JAMA Psychiatry 2016; 73:789-95.
295. Laukkanen T, Kunutsor S, Kauhanen J et al. Sauna bathing is inversely associated with dementia
and Alzheimer's disease in middle-aged Finnish men. Age Ageing 2017; 46:245-49.
296. Kunutsor SK, Khan H, Laukkanen T et al. Joint associations of sauna bathing and
cardiorespiratory fitness on cardiovascular and all-cause mortality risk: a long-term prospective
cohort study. Annals of Medicine 2018; 50:139-46.
297. Scoon GS, Hopkins WG, Mayhew S et al. Effect of post-exercise sauna bathing on the endurance
performance of competitive male runners. Journal of Science and Medicine in Sport 2007;
10:259-62.
298. Kihara T, Biro S, Imamura M et al. Repeated sauna treatment improves vascular endothelial and
cardiac function in patients with chronic heart failure. J Am Coll Cardiol 2002; 39:754-59.
299. Kallstrom M, Soveri I, Oldgren J et al. Effects of sauna bath on heart failure: A systematic review
and meta-analysis. Clinical Cardiology 2018; 41:1491-501.

300. Amano K, Yanagihori R, tEI c. Waon therapyis effective as the treatment of myalgic
encephalomyelitis/Chronic fatigue syndrome. J Jpn Soc Balneol Climatol Phys Med 2015; 78:285-
302.
301. Soejima Y, Munemoto T, Masuda A et al. Effects of Waon therapy on chronic fatigue syndrome:
A pilot study. Intern Med 2015; 54:333-38.
302. Shevchuk N. Adapted cold shower as a potential treatment for depression. Medical Hypotheses
2008; 70:995-1001.
303. Mooventhan A, Nivethitha L. Scientific evidence-based effects of hydrotherapy on various
systems of the body. North American Journal of Medical Sciences 2014; 6:199-209.
304. Patterson B, Yogendra R, Guevara-Coto J et al. Targeting the monocytic-endothelial-platelet axis
with maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae
of COVID (PASC). Research Square 2022.
305. Houghton CA, Fassett RG, Coombes JS. Sulforane: translational research from laboratory bench
to clinic. Nutr Rev 2013; 71:709-26.
306. Kim JK, Park SU. Current potential health benefits of sulforaphane. EXCLI Journal 2016; 15:571-
77.
307. Mokhtari RB, Baluch N, Homayouni TS et al. The role of sulforaphane in cancer
chemoprevention and health benefits: a mini-review. J Cell Commun Signal 2018; 12:91-101.
308. Clarke JD, Hsu A, Riedl K et al. Bioavailability and inter-conversion of sulforaphane and erucin in
human subjects consuming broccoli sprouts or broccoli supplement in a cross-over study design.
Pharmacol Res 2011; 64:456-63.
309. Khandouzi N, Shidfar F, Rajab A et al. The effects of Ginger on fasting blood sugar, hemoglobin
A1C, Apolipoprotein B, Apolipoprotein A-1 and malondialdehyde in type 2 diabetic patients.
Iranian Journal of Pharmaceutical Research 2015; 14:131-40.
310. Gonzalez-Castejon M, Visioli F, Rodrigues-Casado A. Diverse biological activities of dandelion.
Nutr Rev 2012; 70:534-47.
311. Olas B. New perspectives on the effect of dandelion, its food products and other preparations
on the cardiovascular system and its diseases. Nutrients 2022; 14:1350.
312. Tran HT, Gigl M, Le NP et al. In Vitro effect of Taraxacum officinale leaf aqueous extract on the
interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614 and four
mutants. Pharmaceuticals 2021; 14:1055.
313. "Taraxaci folium" and "taraxaci radix". Monography on the Medicinal Uses of Plant Drugs.
End.ed., 499-504. 2003. Stuttgart, Germany, Thieme.
314. Harasstaini OA, Moin S, Tham CL et al. Flavonoid combinations cause synergistic inhibition of
proinflammatory mediator secretion form lipopolysaccharide-induced RAW 264.7 cells.
Inflammation Research 2010; 59:711-21.
315. Marforio TD, Mattioli EJ, Zerbetto F et al. Fullerenes against COVID-19: Repurposing C50 and C70
to clog the active site of SARS-CoV-2 protease. Molecules 2022; 27:1916.
316. Hurmach Vv, Platonov MO, Prylutska SV et al. C60 fullerene against SARS-CoV-2 coronavirus: an
in silico insight. Scientific Reports 2021; 11:17748.
317. Geerts M, de Greef BT, Sopacua M et al. Intravenous immunoglobulin therapy in patients with
painful idiopathic small fiber neuropathy. Neurology 2022; 96:e2534-e2545.
318. Kinnunen S, Hyyppa S, Oksala N et al. alpha-Lipoic acid supplementation enhances heat shock
protein production and decreases post excercise lactic acid concentrations in excercised
standardbred trotters. Research in Veterinary Science 2009; 87:462-67.
319. Hong J, Barnes MJ, Kessler NJ. Case study: Use of vibration therapy in the treatment of diabetic
peripheral small fiber neuropathy. International Journal of Diabetes Mellitus 2015; 3:72-75.

320. Kessler NJ, Hong J. Whole body vibration therapy for painful diabetic peripheral neuropathy: A
Pilot study. Journal of Bodywork & Movement Therapies 2013; 17:518-22.
321. Sanna A, Firinu D, Zavattari P et al. Zinc status and autoimmunity: A systematic review and meta-
analysis. Nutrients 2018; 10:68.
322. Diep PT, Buemann B, Uvnas-Moberg K. Oxytocin, a possible treatment for COVID-19? everything
to gain, nothing to lose. Clinical Neuropsychiatry 2020; 17:192-95.
323. Leuner B, Caponiti JM, Gould E. Oxytocin stimulates adult neurogenesis even under conditions
of stress and elevated glucocorticoids. Hippocampus 2012; 22:861-68.
324. Lee HJ, Macbeth AH, Pagani J et al. Oxytocin: the great facilitator of life. Prog Neurobiol 2009;
88:127-51.
325. MacDonald K, McDonald TM. The peptide that binds: A systematic review of oxytocin and its
prosocial effects in humans. Harv Rev Psychiatry 2010; 18:1-21.
326. Matsushita H, Latt HM, Koga Y et al. Oxytocin and stress: Neural mechanisms, stress-related
disorders,and therapeutic approaches. Neuroscience 2019; 417:1-10.
327. Tzabazis A, Kori S, Mechanic J et al. Oxytocin and migraine headache. Headache 2017; 57:64-75.
328. Krause DN, Warfvinge K, Haanes KA et al. Hormonal influences in migraine - interactions of
oestrogen, oxytocin and CGRP. Nature Reviews Neurology 2021; 17:621-33.
329. Horn S, Bathgate R, Lioutas C et al. Bovine endometrial epithelial cells as a model system to
study oxytocin receptor regulation. Human Reproduction Update 1998; 4:605-14.
330. Freitag K, Sterczyk N, Wendlinger S et al. Spermidine reduces neuroinflammation and soluble
amyloid beta in an Alzheimer's disease mouse model. Journal of Neuroinflammation 2022;
19:172.
331. Schroeder S, Hofer S, Zimmermann A et al. Dietary spermidine improves cognitive function. Cell
Resports 2021; 35:108985.
332. Blaylock RL. Vaccines, depression, and neurodegeneration after age 50 years: another reason to
avoid the recommended vaccines. Medical Veritas 2008; 5:1742-47.
333. Pappa S, Barmparessou Z, Sakka E et al. Depression, Insomnia and post-traumatic stress disorder
in COVID-19 survivors: Role of gender and impact on quality of life. J Pers Med 2022; 12:486.
334. Porter C, Favara M, Scott D et al. Impact of the COVID-19 pandemic on anxiety and depression
symptoms of young people in the Global South: evidence from a four-country cohort study.
medRxiv 2021.
335. Lau T, Horschitz S, Berger S et al. Antidepressant-induced internalization of the serotonin
transporter in serotonergic neurons. FASEB J 2008; 22:1702-14.
336. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation
syndrome: a review of the clinical evidence and the possible mechanisms involved. 4 2013.
337. Hengartner MP, Ploderi M. Newer-generation antidepressants and suicide risk in randomized
controlled trials: A re-analysis of the FDA database. Psychother Psychosom 2019; 88:247-48.
338. Hengartner MP, Amendola S, Kaminski JA. Suicide risk with selective serotonin reuptake
inhibitors and other new-generation antidepressants in adults: a systematic review and meta-
analysis of observational studies. J Epidemiol Community Health 2021; 75:523-30.
339. Breggin PR. Fluvoxamine as a cuase of stimulation, mania and agression with a critical analysis of
the FDA-approved label. International Journal of Risk & Safety Mediciine 2001; 14:71-86.
340. Antidepressants and Violence: the Numbers, RxISK. August17, 2015.
https://rxisk.org/antidepressants-and-violence-the-numbers/ . 2022. RxISK. 6-4-2022.
341. Levenson CW. Zinc: The new antidepressant? Nutr Rev 2006; 64:39-42.
342. Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacological Reports 2005;
57:713-18.

343. Cereda G, Ciappolino V, Boscutti A et al. Zinc as a neuroprotective nutrient for COVID-19-related
neuropsychiatric manifestations: A literature review. Adv Nutr 2022; 13:66-79.
344. Ahmed A, Ghit A, Houjak A, Elkazzaz M. Role of zinc and zinc ionophores in brain health and
depression especially during the COVID-19 pandemic. In: Palmero S, Olivier B, eds. COVID-19
Pandemic, mental health and neuroscience- New Scenarios for understanding and treatment.
IntechOpen; 2022.
345. Ranjbar E, Kasaei MS, Mohammad-Shirazi M et al. Effects of zinc supplementation in patients
with major depression: A randomized clinical trial. Iranian J Psychiatry 2013; 8:73-79.
346. Liu S, Sheng J, Li B et al. Recent advances in non-invasive brain stimulation for major depressive
disorder. Fronteirs in Human Neuroscience 2017; 11:526.
347. Brononi AR, Sampaio-Junior B, Moffa AH et al. Noninvasive brain stimulation in psychiatric
disorders: a primer. Brazilian Journal of Psychiatry 2019; 4:70-81.
348. Dunlop K, Hanlon CA, Downar J. Noninvasive brain stimulation treatments for addiction and
major depression. Ann New York Acad Sci 2017; 1394:31-54.
349. Mutz J, Edgcumbe DR, Brunoni AR et al. Efficacy and acceptability of non-invasive brain
stimulation for the treatment of adult unipolar and bipolar depression: A ystematic review and
meta-analysis of randomised sham-controlled trials. Neuroscience and Biohevioral Reviews
2018; 92:291-303.
350. McClure D, Greenman SC, Koppulu SS et al. A pilot study of safety and efficacy of cranil
electrotherapy stimulation in treatment of bipolar II depression. J Nerv Ment Dis 2015; 203:827-
35.
351. Alda M, Mckinnon M, Blagdon R et al. Methylene blue treatment for residual symptoms of
bipolar disorder: randomised crossover study. Br J Psychiatry 2017; 210:54-60.
352. Naylor GJ, Smith AH, Connelly P. A controlled trial of Methylene Blue in severe depressive
illness. Biological Psychiatry 1987; 22:657-59.
353. Askalsky P, Losifescu DV. Transcranial photobiomodulation for the management of depression:
Current perspectives. Neuropsychiatric Disease and Treatment 2019; 15:3255-72.
354. Benedetti F, Colombo C, Barbini B et al. Morning sunlight reduces length of hospitalization in
bipolar depression. J Affective Disorders 2001; 62:221-23.
355. Schiffer F, Johnston AL, Ravichandran C et al. Psychological benefits 2 and 4 weeks after a single
treatment with near infrared light to the forehead: a pilot study of 10 patients with major
depression and anxiety. Behavioral and Brain Function 2009; 5:46.
356. Safhi MM, Qumayri HM, Masmali AU et al. Thymoquinone and fluoxetine alleviate depression
via attenuating oxidative damage and inflammatory markers in type-2 diabetic rats. Archives of
Physiology & Biochemistry 2019; 125:150-155.
357. Forster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and
depression. Trends in Neurosciences 2013; 38:305-12.
358. Lach G, Schellekens H, Dinan TG et al. Anxiety, depression and the microbiome: A role for Gut
peptides. Neurotherapeutics 2018; 15:36-59.
359. Sharon G. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral
Symptoms in Mice. Cell 2019; 177:1600-1618.
360. Benton D, Williams C, Brown A. Impact of consumng a milk drink containing a probiotic on mood
and cognition. Eur J Clin Nutr 2007; 61:355-61.
361. Rao AV, Bested AC, Beaulne TM et al. A randomized, double-blind, placebo-controlled pilot
study of a probioic in emotional symptoms of chronic fatigue syndrome. Gut Pathogens 2009;
1:6.
362. Din AU, Mazhar M, Waseem M et al. SARS-CoV-2 microbiome dysbiosis linked disorders and
possible probiotic role. Biomedicine & Pharmacotherapy 2021; 133:110947.

363. Hazan S, Stollman N, Bozkurt H et al. Lost microbes of COVID-19: Bifidobacterium,
Faecalibacterium depletion and loss of microbiome diversity associated with SARS-CoV-2
infection severity. BMJ Open Gastroenterology 2022; 9:e000871.
364. Mao YH, Xu Y, Zhao FS et al. Protective effects of konjac glucomannan on gut microbiome with
antibiotic perturbation in mice. Carbohydrate Polymers 2022; 290:119476.
365. Zhang Y, Zhao Y, Yang W et al. Structural complexity of Konjac glucomannan and its derivatives
governs the diversity and outputs of gut microbiota. Carbohydrate Polymers 2022; 292:119639.
366. de Falco B, Amato M, Lanzotti V. Chia seeds products: an overview. Phytochemistry Reviews
2017; 16:745-60.
367. Mostafa-Hedeab G, Al-kuraishy HM, Al-Gareeb AA et al. A raising dawn of pentoxifylline in the
management of inflammatory disorders in Covid-19. Inflammopharmacology 2022.
368. Ng WK, Rosenblatt Y, Brock GB et al. Phosphodiesterase inhibitors in vascular ischemia: A case
report and review of their use in ischemic conditions. Can J Plast Surg 2010; 18:e5-e9.
369. Yang YK. Coenzyme Q10 treatment of cardiovascular disorders of ageing including heart failure,
hypertension and endothelial dysfunction. Clinica Chimica Acta 2015; 450:83-89.
370. Yuan S, Schmidt HM, Wood KC et al. CoenzymeQ in cellular redox regulaion and clinical heart
failure. Free Radical Biology and Medicine 2021; 167:321-34.
371. Yin YJ, Zeng SL, Li YW et al. The effect of coenzyme Q10 plus trimetazidine on acute viral
myocarditis treatment. Am J Transl Res 2021; 13:13854-61.
372. Gutierrez-Mariscal FM, de al Cruz-Ares S, Torres-Pena JD et al. Coenzyme Q10 and
cardiovascular diseases. Antioxidants 2021; 10:906.
373. Sakamoto A, Saotome M, Iguchi K et al. Marine-derived omega-3 polyunsaturated fatty acids
and heart failure: Current understnading for basic to clinical relevance. Int J Mol Sci 2019;
20:4025.
374. Toko H, Morita H, Katakura M et al. Omega-3 fatty acid prevents the development of heart
failure by chnaging fatty acid composition in the heart. Scientific Reports 2020; 10:15553.
375. Liu J, Meng Q, Zheng L et al. Effect of omega-3 polyunsaturated fatty acids on left ventricular
remodeling in chronic heart failure: a systematic review and meta-analysis. Br J Nutr 2022.
376. Usami O, Saitoh H, Ashino Y et al. Acyclovir reduces the duration of fever in patients with
infectious mononucleosis-like illness. Tohoku J Experi Med 2013; 229:137-42.
377. Verma D, Thompson J, Swaminathan S. Spironolactone blocks Epstein-Barr virus production by
inhibiting EBV SM protein function. PNAS 2016; 113:3609-14.
378. Griffith RS, Wlash DE, Myrmel KH et al. Sucess of L-Lysine therapy in frequently recurrent Herpes
simplex infection. Treatment and prophylaxis. Dermatologica 1987; 175:183-90.
379. Griffith RS, Norins AL, Kagan C. A multicentered study of Lysine therapy in Herpes simplex
infection. Dermatologica 1978; 156:257-67.
380. Andreu S, Ripa I, Bello-Morales R et al. Valproic acid and its amidic deratives as new antivirals
against Alphaherpesviruses. Viruses 2020; 12:1356.
381. Gorres KL, Daigle D, Mohanram S et al. Valpromide inhibits ltic cycle reactivation of Epstein-Barr
Virus. mBio 2016; 7:e00113-e00116.
382. Ornaghi S, Davis JN, Gorres KL et al. Mood stabilizers inhibit cytomegalovirus infection. Virology
2016; 499:121-35.
383. Berg K, Bolt G, Andersen H et al. Zinc potentiates the antiviral action of human IFN-alpha
tenfold. J Interferon Cytokine Res 2001; 21:471-74.
384. Skalny AV, Rink L, Ajsuvakova OP et al. Zinc and respiratory tract infections: Perspectives for
COVID-19. Int J Mol Med 2020; 46:17-26.

385. Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM et al. Zinc ionophore activity of Quercetin and
Epigallocatechin-gallate:From Hepa 1-6 cells to a liposome model. J Agric Food Chem 2014;
62:8085-93.
386. Langguth B. Treatment of tinnitus. Curr Opin Otolaryngol Head Neck Surg 2015; 23:361-68.
387. Langguth B. Pharmacological approaches to the treatment of tinnitus. Drug Discovery Today
2010; 15:300-305.
388. Langguth B, Elgoyhen AB, Cederroth CR. Therapeutic approaches to the treatment of tinnitus.
Ann Rev Pharmacol Toxicol 2019; 59:291-313.
389. MartinezDevesda P, Waddell A, Perera R et al. Cognitive behavioral therapy for tinnitus
(Review). Cochrane Database of Syst Rev 2007.
390. Sullivan M, Katon W, Russo J et al. A randomized trial of nortriptyline for severe chronic tinnitus
effects on depression, disability, and tinnitus symptoms. Arch Intern Med 1993; 153:2251-59.
391. Bayar N, Boke B, Turan E et al. Efficacy of amitriptyline in the treatment of subjective tinnitus.
Journal of Otolaryngology 2001; 30:300-303.
392. Zoger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering - A
randomized, double-blind, placebo-controlled study. J Clin Psychopharmacology 2006; 26:32-39.
393. Bahmad FM, Venosa AR, Oliveira CA. Benzodiazepines and GABAergics in treating severe
disabling tinnitus of predominantly cochlear origin. 12 2006;144.
394. Hosseinzadeh A, Kamrava SK, Moore BC et al. Molecular aspects of melatonin treatment in
tinnitus: A review. Current Drug Targets 2019; 20:1112-28.
395. Azevedo AA, Figueirdo rR, Elgoyhen AB et al. Tinnitus treatment with oxytocin: A pilot study.
Front Neurol 2017; 8:494.
396. Han AY, Mukdad L, Long JL et al. Anosmia in COVID-19: Mechanisms and significance. Chemical
senses 2020; 45:423-28.
397. Boesveldt S, Postma EM, Boak D et al. Anosmia - A clinical review. Chemical senses 2017;
42:513-23.
398. Lee MR, Wehring HJ, McMahon RP et al. Effects of adjunctive intranasal oxytocin on olfactory
identification and clinical symptoms in schizophrenia: Results from a randomized double blind
placebo controlled pilot study. Schizophr Ews 2013; 145:110-115.
399. Sorokowaka A, Drechsler E, Karwowski M et al. Effects of olfactory training: a meta-analysis.
Rhinology 2017; 55:17-26.
400. Rashid RA, Zgair A, Al-Ani R. Effect of nasal corticosteroid in the treatment of anosmia due to
COVID-19: A randomised double-blind placebo-controlled study. American Journal of
Otolaryngology-Head and Neck Medicine and Surgery 2021; 42:103033.
401. Weng Z, Patel AB, Panagiotidou S et al. The novel flavone tetramethoxyluteolin is a potent
inhibitor of human mast cells. J Allergy Clin Immunol 2015; 135:1044-52.
402. Patel AB, Theoharides TC. Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory
mediator release via mTOR activation from human mast cells. J Pharmacol Exp Ther 2017;
361:462-71.
403. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of
luteolin. Biofactors 2020; 46:306-8.
404. Theoharides TT, Cholevas C, Polyzoidis K et al. Long-COVID syndrome-associated brain fog and
chemofog: Luteolin to the rescue. Biofactors 2021; 47:232-41.
405. Jacob A, Wu R, Zhou M et al. Mechanism of the anti-inflammatory effect of Curcumin: PPAR-
gamma activation. PPAR Research 2007; 2007:89369.
406. Kakavas S, Karayiannis D, Mastora Z. The complex interplay between immunonutrition, mast
cells, and histamine signaling in COVID-19. Nutrients 2021; 13:3458.

407. Kunnumakkara AB, Harsha C, Banik K et al. Is curcumin bioavailability a problem in humans:
Lessons from clinical trials. Expert Opinion on Drug Metabolism & Toxicology 2019; 15:705-33.
408. Moballegh Nasery M, Abadi B, Poormoghadam D et al. Curcumin delivery mediated by bio-
based nanoparticles: A review. Molecules 2020; 25:689.
409. Valizadeh H, Danshina S, Gencer MZ et al. Nano-curcumin therapy, a promising method in
modulating inflammatory cytokines in COVID-19 patients. International Immunopharmacology
2020; 89:107088.
410. Ahmadi R, Salari S, Reihani H et al. Oral nano-curcumin formulation efficacy in the management
of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical
trial. Food Science & Nutrition 2021; 9:4068-75.
411. Rahimi HR, Nedaeinia R, Shamloo AS et al. Novel delivery system for natural products: Nano-
curcumin formulations. AJP 2016; 6:383.
412. Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and post-Covid-19 illness
may be rooted in mast cell activation syndrome. Int J Infect DIs 2020.
413. Klooker TK, Braak B, Koopman KE et al. The mast cell stabiliser ketotifen decreases visceral
hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.
Gut 2010; 59:1213-21.
414. Wang J, Wang Y, Zhou H et al. Clinical efficacy and safety of ketotifen in treating irritable bowel
syndrome with diarrhea. Eur J Gastroenterol Hepatol 2020; 32:706-12.
415. Nguyen B, Tosti A. Alopecia in COVID-19: Systematic review and meta-analysis. JAAD
International 2022; 7:67-77.
416. Darwin E, Hirt PA, Fertig R et al. Alopecia areata: Review of epidemiology, clinical features,
pathogenesis, and new treatment options. International Journal of Trichology 2018; 10:51-60.
417. Wikramanayake TC, Villasante AC, Mauro LM et al. Prevention and treatment of alopecia areata
with quercetin in the C3H/HeJ mouse model. Cell Stress and Chaperones 2012; 17:267-74.
418. Hamblin MR. Photobiomodulation for the management of alopecia: mechanisms of action,
patient selection and perspectives. Clinical, Cosmetic and Investigational Dermatology 2019;
12:669-78.
419. Torres AE, Lim HW. Photobiomodulation for the management of hair loss. Photodermatol
Photoimmunol Photomed 2021; 37:91-98.
420. Nichols AJ, Hughs OB, Canazza A et al. An open-label evaluator blinded study of the efficacy and
safety of a new nutritional supplement in androgenic alopecia: A pilot study. Journal of Clinical
and Aesthetic Dermatology 2017; 10:52.
421. Karatas F, Sahin S, sever AR et al. Management of hair loss assocaited with endocrine therapy in
patients with breast cancer: an overview. SpringerPlus 2016; 5:585.
422. Harvey CJ. Combined diet and supplementation therapy resolves alopecia areata in apaediatric
patient: A case study. Cureus 2020; 12:e11371.
423. Stoehr JR, Choi JN, Colavincenzo M et al. Off-label use of topical minoxidil in alopecia: A review.
Am J Clin Dermatol 2019; 20:237-50.
424. Gupta AK, Venkataraman M, Talukder M et al. Finasteride for hair loss: a review. Journal of
Dermatological Treatment 2021.
425. Jo SJ, Shin H, Park YW et al. Topical valproic acid increases the hair count in male patients with
androgenic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram
analysis. Journal of Dermatology 2014; 41:285-91.
426. Lee SH, Yoon J, Shin SH et al. Valproic acid induces hair regeneration in murine model and
activates alkaline phosphatase activity in human dermal papilla cells. PloS ONE 2012; 7:e34152.

Changes Include Addition of Nattokinase As First Line Therapy and Reordering of First-And Second-Line Therapies

Uploaded by

Copyright:

Available Formats

Changes Include Addition of Nattokinase As First Line Therapy and Reordering of First-And Second-Line Therapies

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Changes Include Addition of Nattokinase As First Line Therapy and Reordering of First-And Second-Line Therapies

Uploaded by

Copyright:

Available Formats

(Changes include addition of

nattokinase as first line therapy and

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 2

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 3

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 4

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 5

The spike protein of SARS-CoV-2 Figure 1. Complex pathophysiology of spike-related

Many of these antibodies are

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 6

Complications/ injuries caused by COVID injections

• Myocarditis, pericarditis, stress • Thrombocytopenia

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 7

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 8

Figure 2. Vaccine injury is a multi-symptomatic disease*

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 9

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 10

In the event they do contract the virus or

Vaccine-injured patients are frequently

• CBC with differential and platelet count

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 11

Figure 3. Time course of sudden cardiac deaths following COVID-19 vaccination

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 12

• The first is the “typical” post-vaccine, muti-symptomatic syndrome characterized typically by

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 13

Direct oral anticoagulants (DOAC):

Oral Fibrinolytic agents:

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 14

Provisional approach to anticoagulation in the post-vaccine phenotypes

• “Typical” post-vaccine syndrome. Nattokinase 100-200mg (2000 – 4000FU) twice daily is

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 15

o Nattokinase 100-200 mg twice daily

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 16

Intermittent daily fasting or periodic daily fasts

Dosing and administration

Cautions and contraindications

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 17

Women and fasting

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 18

Figure 4. An Intermittent Fasting Plan for Pre-Menopausal Women

Feedback on “productive approach” from a pre-menopausal patient:

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 19

Dosing and administration

▪ If no improvement is noted, a trial of discontinuation should be initiated. Be aware that

▪ If improvements or a reduction in symptoms are noted, a 10-day trial of a higher dose

o Weaning/discontinuation – once patients have clinically improved to a desirable extent on a

Cautions and contraindications

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 20

How much do I weigh? The protocol says…

Moderating physical activity

Dosing and administration

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 21

Dosing and administration

Dosing and administration

Cautions and contraindications

Cautions and contraindications

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 22

Dosing and administration

A 1% methylene blue solution contains 10 mg MB in 1 ml solution (and 0.5 mg/drop). A 1% MB solution

I-RECOVER: Post-Vaccine Treatment Protocol (2023-02-28) 23